-
A.
Naik,
A.
Monjazeb,
J.
Decock
(2019)
The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
Frontiers in Immunology, 10
-
(
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1
antibody, in patients with locally advanced or metastatic breast cancer: a
phase 1b JAVELIN Solid Tumor study. Breast Cancer
Res Treat.
2018;167:671-686.29063313)
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1
antibody, in patients with locally advanced or metastatic breast cancer: a
phase 1b JAVELIN Solid Tumor study. Breast Cancer
Res Treat.
2018;167:671-686.29063313
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1
antibody, in patients with locally advanced or metastatic breast cancer: a
phase 1b JAVELIN Solid Tumor study. Breast Cancer
Res Treat.
2018;167:671-686.29063313,
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1
antibody, in patients with locally advanced or metastatic breast cancer: a
phase 1b JAVELIN Solid Tumor study. Breast Cancer
Res Treat.
2018;167:671-686.29063313
-
(
UnderwoodJC.
Lymphoreticular infiltration in human tumours: prognostic and
biological implications: a review. Br J
Cancer.
1974;30:538-548.4614858)
UnderwoodJC.
Lymphoreticular infiltration in human tumours: prognostic and
biological implications: a review. Br J
Cancer.
1974;30:538-548.4614858
UnderwoodJC.
Lymphoreticular infiltration in human tumours: prognostic and
biological implications: a review. Br J
Cancer.
1974;30:538-548.4614858,
UnderwoodJC.
Lymphoreticular infiltration in human tumours: prognostic and
biological implications: a review. Br J
Cancer.
1974;30:538-548.4614858
-
R.
Salgado,
R.
Salgado,
C.
Denkert,
S.
Demaria,
N.
Sirtaine,
F.
Klauschen,
G.
Pruneri,
S.
Wienert,
G.
Eynden,
F.
Baehner,
F.
Penault-Llorca,
E.
Perez,
E.
Thompson,
W.
Symmans,
A.
Richardson,
J.
Brock,
C.
Criscitiello,
H.
Bailey,
M.
Ignatiadis,
G.
Floris,
J.
Sparano,
Z.
Kos,
T.
Nielsen,
D.
Rimm,
K.
Allison,
J.
Reis-Filho,
S.
Loibl,
C.
Sotiriou,
G.
Viale,
S.
Badve,
S.
Adams,
K.
Willard-Gallo,
S.
Loi
(2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Annals of oncology : official journal of the European Society for Medical Oncology, 26 2
-
C.
Nangia,
P.
Soon-Shiong,
S.
Rabizadeh,
John
Lee,
L.
Sender,
F.
Jones,
M.
Kistler,
K.
Niazi,
T.
Seery,
A.
Rock,
O.
Jafari
(2019)
Complete responses in patients with second-line or greater metastatic triple negative breast cancer (TNBC) following first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK)
Annals of Oncology
-
(
TorreLA
BrayF
SiegelRL
FerlayJ
Lortet-TieulentJ
JemalA.
Global cancer statistics, 2012. CA Cancer
J Clin.
2015;65:87-108.25651787)
TorreLA
BrayF
SiegelRL
FerlayJ
Lortet-TieulentJ
JemalA.
Global cancer statistics, 2012. CA Cancer
J Clin.
2015;65:87-108.25651787
TorreLA
BrayF
SiegelRL
FerlayJ
Lortet-TieulentJ
JemalA.
Global cancer statistics, 2012. CA Cancer
J Clin.
2015;65:87-108.25651787,
TorreLA
BrayF
SiegelRL
FerlayJ
Lortet-TieulentJ
JemalA.
Global cancer statistics, 2012. CA Cancer
J Clin.
2015;65:87-108.25651787
-
Willy
Hugo,
J.
Zaretsky,
Lu
Sun,
Chunying
Song,
B.
Moreno,
S.
Hu-Lieskovan,
B.
Berent-Maoz,
Jia
Pang,
B.
Chmielowski,
Grace
Cherry,
E.
Seja,
Shirley
Lomeli,
X.
Kong,
M.
Kelley,
J.
Sosman,
Douglas
Johnson,
A.
Ribas,
R.
Lo
(2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Cell, 165
-
(
BarecheY
VenetD
IgnatiadisM
, et al. Unravelling triple-negative
breast cancer molecular heterogeneity using an integrative multiomic
analysis. Ann Oncol.
2018;29:895-902.29365031)
BarecheY
VenetD
IgnatiadisM
, et al. Unravelling triple-negative
breast cancer molecular heterogeneity using an integrative multiomic
analysis. Ann Oncol.
2018;29:895-902.29365031
BarecheY
VenetD
IgnatiadisM
, et al. Unravelling triple-negative
breast cancer molecular heterogeneity using an integrative multiomic
analysis. Ann Oncol.
2018;29:895-902.29365031,
BarecheY
VenetD
IgnatiadisM
, et al. Unravelling triple-negative
breast cancer molecular heterogeneity using an integrative multiomic
analysis. Ann Oncol.
2018;29:895-902.29365031
-
(
DevaudC
JohnLB
WestwoodJA
DarcyPK
KershawMH.
Immune modulation of the tumor microenvironment for enhancing
cancer immunotherapy. Oncoimmunology.
2013;2:e25961.)
DevaudC
JohnLB
WestwoodJA
DarcyPK
KershawMH.
Immune modulation of the tumor microenvironment for enhancing
cancer immunotherapy. Oncoimmunology.
2013;2:e25961.
DevaudC
JohnLB
WestwoodJA
DarcyPK
KershawMH.
Immune modulation of the tumor microenvironment for enhancing
cancer immunotherapy. Oncoimmunology.
2013;2:e25961.,
DevaudC
JohnLB
WestwoodJA
DarcyPK
KershawMH.
Immune modulation of the tumor microenvironment for enhancing
cancer immunotherapy. Oncoimmunology.
2013;2:e25961.
-
W.
Hendrickx,
I.
Simeone,
Samreen
Anjum,
Y.
Mokrab,
F.
Bertucci,
P.
Finetti,
G.
Curigliano,
B.
Seliger,
L.
Cerulo,
S.
Tomei,
L.
Delogu,
C.
Maccalli,
E.
Wang,
L.
Miller,
F.
Marincola,
M.
Ceccarelli,
D.
Bedognetti
(2017)
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
Oncoimmunology, 6
-
(
MiyashitaM
SasanoH
TamakiK
, et al. Prognostic significance of
tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and
alterations in these parameters after neoadjuvant chemotherapy in
triple-negative breast cancer: a retrospective multicenter
study. Breast Cancer Res.
2015;17:124.26341640)
MiyashitaM
SasanoH
TamakiK
, et al. Prognostic significance of
tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and
alterations in these parameters after neoadjuvant chemotherapy in
triple-negative breast cancer: a retrospective multicenter
study. Breast Cancer Res.
2015;17:124.26341640
MiyashitaM
SasanoH
TamakiK
, et al. Prognostic significance of
tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and
alterations in these parameters after neoadjuvant chemotherapy in
triple-negative breast cancer: a retrospective multicenter
study. Breast Cancer Res.
2015;17:124.26341640,
MiyashitaM
SasanoH
TamakiK
, et al. Prognostic significance of
tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and
alterations in these parameters after neoadjuvant chemotherapy in
triple-negative breast cancer: a retrospective multicenter
study. Breast Cancer Res.
2015;17:124.26341640
-
(
DavisAA
PatelVG.
The role of PD-L1 expression as a predictive biomarker: an
analysis of all US Food and Drug Administration (FDA) approvals of immune
checkpoint inhibitors. J Immunother Cancer.
2019;7:278.31655605)
DavisAA
PatelVG.
The role of PD-L1 expression as a predictive biomarker: an
analysis of all US Food and Drug Administration (FDA) approvals of immune
checkpoint inhibitors. J Immunother Cancer.
2019;7:278.31655605
DavisAA
PatelVG.
The role of PD-L1 expression as a predictive biomarker: an
analysis of all US Food and Drug Administration (FDA) approvals of immune
checkpoint inhibitors. J Immunother Cancer.
2019;7:278.31655605,
DavisAA
PatelVG.
The role of PD-L1 expression as a predictive biomarker: an
analysis of all US Food and Drug Administration (FDA) approvals of immune
checkpoint inhibitors. J Immunother Cancer.
2019;7:278.31655605
-
(
SenkusE
CardosoF
PaganiO.
Time for more optimism in metastatic breast
cancer?
Cancer Treat Rev.
2014;40:220-228.24126121)
SenkusE
CardosoF
PaganiO.
Time for more optimism in metastatic breast
cancer?
Cancer Treat Rev.
2014;40:220-228.24126121
SenkusE
CardosoF
PaganiO.
Time for more optimism in metastatic breast
cancer?
Cancer Treat Rev.
2014;40:220-228.24126121,
SenkusE
CardosoF
PaganiO.
Time for more optimism in metastatic breast
cancer?
Cancer Treat Rev.
2014;40:220-228.24126121
-
A.
Jemal,
F.
Bray,
Melissa
Center,
J.
Ferlay,
Elizabeth
Ward,
D.
Forman
(2011)
Global cancer statistics
CA: A Cancer Journal for Clinicians, 61
-
(
MolineroL
LiY
ChangCW
, et al. Tumor immune
microenvironment and genomic evolution in a patient with metastatic triple
negative breast cancer and a complete response to
atezolizumab. J Immunother Cancer.
2019;7:274.31647026)
MolineroL
LiY
ChangCW
, et al. Tumor immune
microenvironment and genomic evolution in a patient with metastatic triple
negative breast cancer and a complete response to
atezolizumab. J Immunother Cancer.
2019;7:274.31647026
MolineroL
LiY
ChangCW
, et al. Tumor immune
microenvironment and genomic evolution in a patient with metastatic triple
negative breast cancer and a complete response to
atezolizumab. J Immunother Cancer.
2019;7:274.31647026,
MolineroL
LiY
ChangCW
, et al. Tumor immune
microenvironment and genomic evolution in a patient with metastatic triple
negative breast cancer and a complete response to
atezolizumab. J Immunother Cancer.
2019;7:274.31647026
-
H.
Han,
S.
Diab,
C.
Alemany,
R.
Basho,
U.
Brown-Glaberman,
J.
Meisel,
T.
Pluard,
J.
Cortés,
P.
Dillon,
J.
Ettl,
S.
Kuemmel,
L.
Sánchez,
Mafalda
Oliveira,
J.
O’Shaughnessy,
S.
Papish,
R.
Sinha,
D.
Sterrenberg,
E.
Stringer-Reasor,
M.
Tsai,
R.
Vázquez,
R.
Wuerstlein,
Yinghui
Wang,
Zejing
Wang,
V.
Boni
(2020)
Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Cancer Research, 80
-
(
ChenG
EmensLA.
Chemoimmunotherapy: reengineering tumor immunity.
Cancer Immunol Immunother.
2013;62:203-216.23389507)
ChenG
EmensLA.
Chemoimmunotherapy: reengineering tumor immunity.
Cancer Immunol Immunother.
2013;62:203-216.23389507
ChenG
EmensLA.
Chemoimmunotherapy: reengineering tumor immunity.
Cancer Immunol Immunother.
2013;62:203-216.23389507,
ChenG
EmensLA.
Chemoimmunotherapy: reengineering tumor immunity.
Cancer Immunol Immunother.
2013;62:203-216.23389507
-
(
CapassoA
LangJ
PittsTM
, et al. Characterization of immune
responses to anti-PD-1 mono and combination immunotherapy in hematopoietic
humanized mice implanted with tumor xenografts. J
Immunother Cancer.
2019;7:37.30736857)
CapassoA
LangJ
PittsTM
, et al. Characterization of immune
responses to anti-PD-1 mono and combination immunotherapy in hematopoietic
humanized mice implanted with tumor xenografts. J
Immunother Cancer.
2019;7:37.30736857
CapassoA
LangJ
PittsTM
, et al. Characterization of immune
responses to anti-PD-1 mono and combination immunotherapy in hematopoietic
humanized mice implanted with tumor xenografts. J
Immunother Cancer.
2019;7:37.30736857,
CapassoA
LangJ
PittsTM
, et al. Characterization of immune
responses to anti-PD-1 mono and combination immunotherapy in hematopoietic
humanized mice implanted with tumor xenografts. J
Immunother Cancer.
2019;7:37.30736857
-
R.
Andtbacka,
M.
Ross,
I.
Puzanov,
M.
Milhem,
F.
Collichio,
K.
Delman,
T.
Amatruda,
J.
Zager,
L.
Cranmer,
E.
Hsueh,
Lisa
Chen,
M.
Shilkrut,
H.
Kaufman
(2016)
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Annals of Surgical Oncology, 23
-
E.
Mittendorf,
A.
Philips,
F.
Meric-Bernstam,
N.
Qiao,
Yun
Wu,
S.
Harrington,
X.
Su,
Ying
Wang,
A.
González-Angulo,
A.
Akcakanat,
A.
Chawla,
M.
Curran,
P.
Hwu,
P.
Sharma,
J.
Litton,
J.
Molldrem,
G.
Alatrash
(2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Cancer Immunology Research, 2
-
Reem
Saleh,
Rowaida
Taha,
V.
Nair,
Nehad
Alajez,
E.
Elkord
(2019)
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
Cancers, 11
-
S.
Nizar,
J.
Copier,
Brendan
Meyer,
M.
Bodman-Smith,
C.
Galustian,
Devinder
Kumar,
A.
Dalgleish
(2009)
T-regulatory cell modulation: the future of cancer immunotherapy?
British Journal of Cancer, 100
-
M.
Miyashita,
H.
Sasano,
K.
Tamaki,
H.
Hirakawa,
Yayoi
Takahashi,
Saki
Nakagawa,
G.
Watanabe,
H.
Tada,
A.
Suzuki,
N.
Ohuchi,
T.
Ishida
(2015)
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study
Breast Cancer Research : BCR, 17
-
(
CallahanR
HurvitzS.
Human epidermal growth factor receptor-2-positive breast cancer:
current management of early, advanced, and recurrent
disease. Curr Opin Obstet Gynecol.
2011;23:37-43.21500375)
CallahanR
HurvitzS.
Human epidermal growth factor receptor-2-positive breast cancer:
current management of early, advanced, and recurrent
disease. Curr Opin Obstet Gynecol.
2011;23:37-43.21500375
CallahanR
HurvitzS.
Human epidermal growth factor receptor-2-positive breast cancer:
current management of early, advanced, and recurrent
disease. Curr Opin Obstet Gynecol.
2011;23:37-43.21500375,
CallahanR
HurvitzS.
Human epidermal growth factor receptor-2-positive breast cancer:
current management of early, advanced, and recurrent
disease. Curr Opin Obstet Gynecol.
2011;23:37-43.21500375
-
(
U.S. Food and Drug Administration. FDA approves
pembrolizumab for high-risk early-stage triple-negative breast
cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_medium=email&utm_source=govdelivery.
Published 2021. Accessed November 12,
2021.)
U.S. Food and Drug Administration. FDA approves
pembrolizumab for high-risk early-stage triple-negative breast
cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_medium=email&utm_source=govdelivery.
Published 2021. Accessed November 12,
2021.
U.S. Food and Drug Administration. FDA approves
pembrolizumab for high-risk early-stage triple-negative breast
cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_medium=email&utm_source=govdelivery.
Published 2021. Accessed November 12,
2021.,
U.S. Food and Drug Administration. FDA approves
pembrolizumab for high-risk early-stage triple-negative breast
cancer, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer?utm_medium=email&utm_source=govdelivery.
Published 2021. Accessed November 12,
2021.
-
E.
Rocca,
M.
Dispinzieri,
L.
Lozza,
G.
Mariani,
S.
Cosimo,
M.
Gennaro,
R.
Valdagni,
M.
Santis
(2018)
Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer
Medical Oncology, 36
-
J.
Uram,
Hao
Wang,
Bjarne
Bartlett,
H.
Kemberling,
A.
Eyring,
A.
Skora,
N.
Azad,
D.
Laheru,
R.
Donehower,
Brandon
Luber,
T.
Crocenzi,
G.
Fisher,
Steven
Duffy,
James
Lee,
M.
Koshiji,
J.
Eshleman,
R.
Anders,
B.
Vogelstein,
L.
Diaz
(2015)
PD-1 blockade in tumors with mismatch repair deficiency.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18_suppl
-
(
HugoW
ZaretskyJM
SunL
, et al. Genomic and transcriptomic
features of response to anti-PD-1 therapy in metastatic
melanoma. Cell.
2016;165:35-44.26997480)
HugoW
ZaretskyJM
SunL
, et al. Genomic and transcriptomic
features of response to anti-PD-1 therapy in metastatic
melanoma. Cell.
2016;165:35-44.26997480
HugoW
ZaretskyJM
SunL
, et al. Genomic and transcriptomic
features of response to anti-PD-1 therapy in metastatic
melanoma. Cell.
2016;165:35-44.26997480,
HugoW
ZaretskyJM
SunL
, et al. Genomic and transcriptomic
features of response to anti-PD-1 therapy in metastatic
melanoma. Cell.
2016;165:35-44.26997480
-
F.
Hodi,
V.
Chiarion-Sileni,
R.
Gonzalez,
J.
Grob,
P.
Rutkowski,
C.
Cowey,
C.
Lao,
D.
Schadendorf,
J.
Wagstaff,
R.
Dummer,
P.
Ferrucci,
M.
Smylie,
A.
Hill,
D.
Hogg,
I.
Márquez-Rodas,
Joel
Jiang,
J.
Rizzo,
J.
Larkin,
J.
Wolchok
(2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
The Lancet. Oncology, 19 11
-
L.
Emens,
Jean-Pascal
Machiels,
Reilly
Rt,
Elizabeth
Jaffee
(2001)
Chemotherapy: friend or foe to cancer vaccines?
Current opinion in molecular therapeutics, 3 1
-
(2021)
and Drug Administration
-
(
ZavalishinaL
TsimafeyeuI
PovilaititeP
, et al. RUSSCO-RSP comparative study
of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial
bladder cancer. Virchows Arch.
2018;473:719-724.30209552)
ZavalishinaL
TsimafeyeuI
PovilaititeP
, et al. RUSSCO-RSP comparative study
of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial
bladder cancer. Virchows Arch.
2018;473:719-724.30209552
ZavalishinaL
TsimafeyeuI
PovilaititeP
, et al. RUSSCO-RSP comparative study
of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial
bladder cancer. Virchows Arch.
2018;473:719-724.30209552,
ZavalishinaL
TsimafeyeuI
PovilaititeP
, et al. RUSSCO-RSP comparative study
of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial
bladder cancer. Virchows Arch.
2018;473:719-724.30209552
-
Marios
Papadimitriou,
G.
Mountzios,
C.
Papadimitriou
(2018)
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Cancer treatment reviews, 67
-
A.
Zingoni,
C.
Fionda,
C.
Borrelli,
M.
Cippitelli,
A.
Santoni,
A.
Soriani
(2017)
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Frontiers in Immunology, 8
-
(
KuehnHS
OuyangW
LoB
, et al. Immune dysregulation in
human subjects with heterozygous germline mutations in
CTLA4. Science.
2014;345:1623-1627.25213377)
KuehnHS
OuyangW
LoB
, et al. Immune dysregulation in
human subjects with heterozygous germline mutations in
CTLA4. Science.
2014;345:1623-1627.25213377
KuehnHS
OuyangW
LoB
, et al. Immune dysregulation in
human subjects with heterozygous germline mutations in
CTLA4. Science.
2014;345:1623-1627.25213377,
KuehnHS
OuyangW
LoB
, et al. Immune dysregulation in
human subjects with heterozygous germline mutations in
CTLA4. Science.
2014;345:1623-1627.25213377
-
Liu Z,
Li M,
Jiang Z,
Wang X
(2018)
A comprehensive immunologic portrait of triple-negative breast cancer
Transl Oncol., 11
-
M.
Postow,
J.
Chesney,
A.
Pavlick,
C.
Robert,
K.
Grossmann,
D.
McDermott,
G.
Linette,
N.
Meyer,
J.
Giguere,
S.
Agarwala,
M.
Shaheen,
M.
Ernstoff,
D.
Minor,
A.
Salama,
Matthew
Taylor,
P.
Ott,
L.
Rollin,
C.
Horak,
P.
Gagnier,
J.
Wolchok,
F.
Hodi
(2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
The New England journal of medicine, 372 21
-
H.
Rugo,
S.
Loi,
S.
Adams,
P.
Schmid,
A.
Schneeweiss,
C.
Barrios,
H.
Iwata,
V.
Diéras,
E.
Winer,
M.
Kockx,
D.
Peeters,
S.
Chui,
Jennifer
Lin,
Anh
Nguyen-Duc,
G.
Viale,
L.
Molinero,
L.
Emens
(2021)
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer
JNCI Journal of the National Cancer Institute, 113
-
(
SnyderA
MakarovV
MerghoubT
, et al. Genetic basis for clinical
response to CTLA-4 blockade in melanoma. N Engl J
Med.
2014;371:2189-2199.25409260)
SnyderA
MakarovV
MerghoubT
, et al. Genetic basis for clinical
response to CTLA-4 blockade in melanoma. N Engl J
Med.
2014;371:2189-2199.25409260
SnyderA
MakarovV
MerghoubT
, et al. Genetic basis for clinical
response to CTLA-4 blockade in melanoma. N Engl J
Med.
2014;371:2189-2199.25409260,
SnyderA
MakarovV
MerghoubT
, et al. Genetic basis for clinical
response to CTLA-4 blockade in melanoma. N Engl J
Med.
2014;371:2189-2199.25409260
-
R.
Dent,
M.
Trudeau,
K.
Pritchard,
W.
Hanna,
H.
Kahn,
C.
Sawka,
L.
Lickley,
E.
Rawlinson,
P.
Sun,
S.
Narod
(2007)
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Clinical Cancer Research, 13
-
(
JiangDM
FylesA
NguyenLT
, et al. Phase I study of local
radiation and tremelimumab in patients with inoperable locally recurrent or
metastatic breast cancer. Oncotarget.
2019;10:2947-2958.31105877)
JiangDM
FylesA
NguyenLT
, et al. Phase I study of local
radiation and tremelimumab in patients with inoperable locally recurrent or
metastatic breast cancer. Oncotarget.
2019;10:2947-2958.31105877
JiangDM
FylesA
NguyenLT
, et al. Phase I study of local
radiation and tremelimumab in patients with inoperable locally recurrent or
metastatic breast cancer. Oncotarget.
2019;10:2947-2958.31105877,
JiangDM
FylesA
NguyenLT
, et al. Phase I study of local
radiation and tremelimumab in patients with inoperable locally recurrent or
metastatic breast cancer. Oncotarget.
2019;10:2947-2958.31105877
-
Y.
Bareche,
D.
Venet,
M.
Ignatiadis,
P.
Aftimos,
M.
Piccart,
F.
Rothé,
C.
Sotiriou
(2018)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Annals of Oncology, 29
-
L.
Dirix,
I.
Takács,
G.
Jerusalem,
P.
Nikolinakos,
H.
Arkenau,
A.
Forero-Torres,
R.
Boccia,
M.
Lippman,
R.
Somer,
M.
Šmakal,
L.
Emens,
B.
Hrinczenko,
W.
Edenfield,
J.
Gurtler,
A.
Heydebreck,
H.
Grote,
K.
Chin,
E.
Hamilton
(2017)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Breast Cancer Research and Treatment, 167
-
N.
Rizvi,
M.
Hellmann,
A.
Snyder,
P.
Kvistborg,
V.
Makarov,
J.
Havel,
William
Lee,
Jianda
Yuan,
P.
Wong,
Teresa
Ho,
Martin
Miller,
N.
Rekhtman,
A.
Moreira,
Fawzia
Ibrahim,
Cameron
Bruggeman,
Billel
Gasmi,
R.
Zappasodi,
Y.
Maeda,
C.
Sander,
E.
Garon,
T.
Merghoub,
J.
Wolchok,
T.
Schumacher,
T.
Chan
(2015)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science, 348
-
S.
Loi
(2013)
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
Oncoimmunology, 2
-
P.
Kantoff,
C.
Higano,
N.
Shore,
E.
Berger,
E.
Small,
D.
Penson,
C.
Redfern,
A.
Ferrari,
R.
Dreicer,
R.
Sims,
Yi
Xu,
M.
Frohlich,
P.
Schellhammer
(2010)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
The New England journal of medicine, 363 5
-
(
MastellerEL
ChuangE
MullenAC
ReinerSL
ThompsonCB.
Structural analysis of CTLA-4 function in vivo.
J Immunol.
2000;164:5319-5327.10799894)
MastellerEL
ChuangE
MullenAC
ReinerSL
ThompsonCB.
Structural analysis of CTLA-4 function in vivo.
J Immunol.
2000;164:5319-5327.10799894
MastellerEL
ChuangE
MullenAC
ReinerSL
ThompsonCB.
Structural analysis of CTLA-4 function in vivo.
J Immunol.
2000;164:5319-5327.10799894,
MastellerEL
ChuangE
MullenAC
ReinerSL
ThompsonCB.
Structural analysis of CTLA-4 function in vivo.
J Immunol.
2000;164:5319-5327.10799894
-
M.
Sobral-Leite,
K.
Vijver,
M.
Michaut,
Rianne
Linden,
G.
Hooijer,
H.
Horlings,
T.
Severson,
A.
Mulligan,
Nayana
Weerasooriya,
J.
Sanders,
A.
Glas,
D.
Wehkamp,
L.
Mittempergher,
K.
Kersten,
A.
Cimino-Mathews,
D.
Peters,
E.
Hooijberg,
A.
Broeks,
M.
Vijver,
R.
Bernards,
I.
Andrulis,
M.
Kok,
K.
Visser,
M.
Schmidt
(2018)
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
OncoImmunology, 7
-
(
AlistarA
ChouJW
NagallaS
BlackMA
D’AgostinoRJr
MillerLD.
Dual roles for immune metagenes in breast cancer prognosis and
therapy prediction. Genome Med.
2014;6:80.25419236)
AlistarA
ChouJW
NagallaS
BlackMA
D’AgostinoRJr
MillerLD.
Dual roles for immune metagenes in breast cancer prognosis and
therapy prediction. Genome Med.
2014;6:80.25419236
AlistarA
ChouJW
NagallaS
BlackMA
D’AgostinoRJr
MillerLD.
Dual roles for immune metagenes in breast cancer prognosis and
therapy prediction. Genome Med.
2014;6:80.25419236,
AlistarA
ChouJW
NagallaS
BlackMA
D’AgostinoRJr
MillerLD.
Dual roles for immune metagenes in breast cancer prognosis and
therapy prediction. Genome Med.
2014;6:80.25419236
-
(
JanuškevičienėI
PetrikaitėV.
Heterogeneity of breast cancer: the importance of interaction
between different tumor cell populations. Life
Sci.
2019;239:117009.31669239)
JanuškevičienėI
PetrikaitėV.
Heterogeneity of breast cancer: the importance of interaction
between different tumor cell populations. Life
Sci.
2019;239:117009.31669239
JanuškevičienėI
PetrikaitėV.
Heterogeneity of breast cancer: the importance of interaction
between different tumor cell populations. Life
Sci.
2019;239:117009.31669239,
JanuškevičienėI
PetrikaitėV.
Heterogeneity of breast cancer: the importance of interaction
between different tumor cell populations. Life
Sci.
2019;239:117009.31669239
-
(
HuJB
RavichandranS
RushingC
, et al. Higher BMI, but not
sarcopenia, is associated with pembrolizumab-related toxicity in patients
with advanced melanoma. Anticancer Res.
2020;40:5245-5254.32878813)
HuJB
RavichandranS
RushingC
, et al. Higher BMI, but not
sarcopenia, is associated with pembrolizumab-related toxicity in patients
with advanced melanoma. Anticancer Res.
2020;40:5245-5254.32878813
HuJB
RavichandranS
RushingC
, et al. Higher BMI, but not
sarcopenia, is associated with pembrolizumab-related toxicity in patients
with advanced melanoma. Anticancer Res.
2020;40:5245-5254.32878813,
HuJB
RavichandranS
RushingC
, et al. Higher BMI, but not
sarcopenia, is associated with pembrolizumab-related toxicity in patients
with advanced melanoma. Anticancer Res.
2020;40:5245-5254.32878813
-
(
HanH
DiabS
AlemanyC
, et al. Abstract PD1-06: open label
phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab
for first-line treatment of patients with unresectable locally-advanced or
metastatic triple-negative breast cancer. Cancer
Res. 2020;80:PD1-06.)
HanH
DiabS
AlemanyC
, et al. Abstract PD1-06: open label
phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab
for first-line treatment of patients with unresectable locally-advanced or
metastatic triple-negative breast cancer. Cancer
Res. 2020;80:PD1-06.
HanH
DiabS
AlemanyC
, et al. Abstract PD1-06: open label
phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab
for first-line treatment of patients with unresectable locally-advanced or
metastatic triple-negative breast cancer. Cancer
Res. 2020;80:PD1-06.,
HanH
DiabS
AlemanyC
, et al. Abstract PD1-06: open label
phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab
for first-line treatment of patients with unresectable locally-advanced or
metastatic triple-negative breast cancer. Cancer
Res. 2020;80:PD1-06.
-
B.
Xia,
R.
Herbst
(2018)
Management of Advanced Non–Small Cell Lung Cancer
-
(
SchumacherTN
SchreiberRD.
Neoantigens in cancer immunotherapy.
Science.
2015;348:69-74.25838375)
SchumacherTN
SchreiberRD.
Neoantigens in cancer immunotherapy.
Science.
2015;348:69-74.25838375
SchumacherTN
SchreiberRD.
Neoantigens in cancer immunotherapy.
Science.
2015;348:69-74.25838375,
SchumacherTN
SchreiberRD.
Neoantigens in cancer immunotherapy.
Science.
2015;348:69-74.25838375
-
(
LeDT
UramJN
WangH
, et al. PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med.
2015;372:2509-2520.26028255)
LeDT
UramJN
WangH
, et al. PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med.
2015;372:2509-2520.26028255
LeDT
UramJN
WangH
, et al. PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med.
2015;372:2509-2520.26028255,
LeDT
UramJN
WangH
, et al. PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med.
2015;372:2509-2520.26028255
-
(
European Medicines Agency. EMA reminds
physicians to use Tecentriq with nab-paclitaxel for treating breast
cancer, https://www.ema.europa.eu/en/news/ema-reminds-physicians-use-tecentriq-nab-paclitaxel-treating-breast-cancer.
Published 2020. Updated May
21, 2021. Accessed November 28,
2021.)
European Medicines Agency. EMA reminds
physicians to use Tecentriq with nab-paclitaxel for treating breast
cancer, https://www.ema.europa.eu/en/news/ema-reminds-physicians-use-tecentriq-nab-paclitaxel-treating-breast-cancer.
Published 2020. Updated May
21, 2021. Accessed November 28,
2021.
European Medicines Agency. EMA reminds
physicians to use Tecentriq with nab-paclitaxel for treating breast
cancer, https://www.ema.europa.eu/en/news/ema-reminds-physicians-use-tecentriq-nab-paclitaxel-treating-breast-cancer.
Published 2020. Updated May
21, 2021. Accessed November 28,
2021.,
European Medicines Agency. EMA reminds
physicians to use Tecentriq with nab-paclitaxel for treating breast
cancer, https://www.ema.europa.eu/en/news/ema-reminds-physicians-use-tecentriq-nab-paclitaxel-treating-breast-cancer.
Published 2020. Updated May
21, 2021. Accessed November 28,
2021.
-
(
Abdel-LatifM
YounessRA.
Why natural killer cells in triple negative breast
cancer?
World J Clin Oncol.
2020;11:464-476.32821652)
Abdel-LatifM
YounessRA.
Why natural killer cells in triple negative breast
cancer?
World J Clin Oncol.
2020;11:464-476.32821652
Abdel-LatifM
YounessRA.
Why natural killer cells in triple negative breast
cancer?
World J Clin Oncol.
2020;11:464-476.32821652,
Abdel-LatifM
YounessRA.
Why natural killer cells in triple negative breast
cancer?
World J Clin Oncol.
2020;11:464-476.32821652
-
S.
Bonvalot,
A.
Gronchi,
C.
Péchoux,
C.
Swallow,
D.
Strauss,
P.
Meeus,
F.
Coevorden,
S.
Stoldt,
E.
Stoeckle,
P.
Rutkowski,
C.
Sangalli,
C.
Honoré,
M.
Rastrelli,
C.
Raut,
P.
Chung,
M.
Fiore,
S.
Litière,
S.
Marréaud,
H.
Gelderblom,
R.
Haas
(2019)
STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.
Journal of Clinical Oncology
-
(
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,
https://clinicaltrials.gov/ct2/show/study/NCT04468061. Published
2020. Updated January
11, 2022. Accessed March 11,
2022.)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,
https://clinicaltrials.gov/ct2/show/study/NCT04468061. Published
2020. Updated January
11, 2022. Accessed March 11,
2022.
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,
https://clinicaltrials.gov/ct2/show/study/NCT04468061. Published
2020. Updated January
11, 2022. Accessed March 11,
2022.,
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,
https://clinicaltrials.gov/ct2/show/study/NCT04468061. Published
2020. Updated January
11, 2022. Accessed March 11,
2022.
-
(
HendrickxW
SimeoneI
AnjumS
, et al. Identification of genetic
determinants of breast cancer immune phenotypes by integrative genome-scale
analysis. Oncoimmunology.
2017;6:e1253654.28344865)
HendrickxW
SimeoneI
AnjumS
, et al. Identification of genetic
determinants of breast cancer immune phenotypes by integrative genome-scale
analysis. Oncoimmunology.
2017;6:e1253654.28344865
HendrickxW
SimeoneI
AnjumS
, et al. Identification of genetic
determinants of breast cancer immune phenotypes by integrative genome-scale
analysis. Oncoimmunology.
2017;6:e1253654.28344865,
HendrickxW
SimeoneI
AnjumS
, et al. Identification of genetic
determinants of breast cancer immune phenotypes by integrative genome-scale
analysis. Oncoimmunology.
2017;6:e1253654.28344865
-
G.
O’Brien,
R.
Cahill,
D.
Bouchier-Hayes,
D.
Bouchier‐Hayes,
H.
Redmond
(2006)
Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma
Irish Journal of Medical Science, 175
-
Zhixian
Liu,
Mengyuan
Li,
Zehang
Jiang,
Xiaosheng
Wang
(2017)
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Translational Oncology, 11
-
D.
Miles,
J.
Gligorov,
F.
André,
D.
Cameron,
A.
Schneeweiss,
C.
Barrios,
Xu
Bh,
A.
Wardley,
D.
Kaen,
L.
Andrade,
V.
Semiglazov,
M.
Reinisch,
M.
Patre,
L.
Morales,
K.
Russell,
M.
Donica,
J.
O’Shaughnessy
(2020)
LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Annals of Oncology, 31
-
A.
Davis,
V.
Patel
(2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Journal for Immunotherapy of Cancer, 7
-
(
TopalianSL
SznolM
McDermottDF
, et al. Survival, durable tumor
remission, and long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol.
2014;32:1020-1030.24590637)
TopalianSL
SznolM
McDermottDF
, et al. Survival, durable tumor
remission, and long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol.
2014;32:1020-1030.24590637
TopalianSL
SznolM
McDermottDF
, et al. Survival, durable tumor
remission, and long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol.
2014;32:1020-1030.24590637,
TopalianSL
SznolM
McDermottDF
, et al. Survival, durable tumor
remission, and long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol.
2014;32:1020-1030.24590637
-
(
WeberJS
KahlerKC
HauschildA.
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol.
2012;30:2691-2697.22614989)
WeberJS
KahlerKC
HauschildA.
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol.
2012;30:2691-2697.22614989
WeberJS
KahlerKC
HauschildA.
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol.
2012;30:2691-2697.22614989,
WeberJS
KahlerKC
HauschildA.
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol.
2012;30:2691-2697.22614989
-
(
NaikA
MonjazebAM
DecockJ.
The obesity paradox in cancer, tumor immunology, and
immunotherapy: potential therapeutic implications in triple negative breast
cancer. Front Immunol.
2019;10:1940.)
NaikA
MonjazebAM
DecockJ.
The obesity paradox in cancer, tumor immunology, and
immunotherapy: potential therapeutic implications in triple negative breast
cancer. Front Immunol.
2019;10:1940.
NaikA
MonjazebAM
DecockJ.
The obesity paradox in cancer, tumor immunology, and
immunotherapy: potential therapeutic implications in triple negative breast
cancer. Front Immunol.
2019;10:1940.,
NaikA
MonjazebAM
DecockJ.
The obesity paradox in cancer, tumor immunology, and
immunotherapy: potential therapeutic implications in triple negative breast
cancer. Front Immunol.
2019;10:1940.
-
M.
Abdel-Latif,
R.
Youness
(2020)
Why natural killer cells in triple negative breast cancer?
World Journal of Clinical Oncology, 11
-
(
NizarS
CopierJ
MeyerB
, et al. T-regulatory cell
modulation: the future of cancer immunotherapy?
Br J Cancer.
2009;100:1697-1703.19384299)
NizarS
CopierJ
MeyerB
, et al. T-regulatory cell
modulation: the future of cancer immunotherapy?
Br J Cancer.
2009;100:1697-1703.19384299
NizarS
CopierJ
MeyerB
, et al. T-regulatory cell
modulation: the future of cancer immunotherapy?
Br J Cancer.
2009;100:1697-1703.19384299,
NizarS
CopierJ
MeyerB
, et al. T-regulatory cell
modulation: the future of cancer immunotherapy?
Br J Cancer.
2009;100:1697-1703.19384299
-
P.
Guermonprez,
J.
Valladeau,
L.
Zitvogel,
C.
Théry,
S.
Amigorena
(2002)
Antigen presentation and T cell stimulation by dendritic cells.
Annual review of immunology, 20
-
T.
Sugie
(2018)
Immunotherapy for metastatic breast cancer.
Chinese clinical oncology, 7 3
-
Michael
Rooney,
S.
Shukla,
Catherine
Wu,
G.
Getz,
N.
Hacohen
(2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Cell, 160
-
(
WenYH
BrogiE
ZengZ
, et al. DNA mismatch repair
deficiency in breast carcinoma: a pilot study of triple-negative and
non-triple-negative tumors. Am J Surg
Pathol.
2012;36:1700-1708.22992699)
WenYH
BrogiE
ZengZ
, et al. DNA mismatch repair
deficiency in breast carcinoma: a pilot study of triple-negative and
non-triple-negative tumors. Am J Surg
Pathol.
2012;36:1700-1708.22992699
WenYH
BrogiE
ZengZ
, et al. DNA mismatch repair
deficiency in breast carcinoma: a pilot study of triple-negative and
non-triple-negative tumors. Am J Surg
Pathol.
2012;36:1700-1708.22992699,
WenYH
BrogiE
ZengZ
, et al. DNA mismatch repair
deficiency in breast carcinoma: a pilot study of triple-negative and
non-triple-negative tumors. Am J Surg
Pathol.
2012;36:1700-1708.22992699
-
J.
Cortés,
D.
Cescon,
H.
Rugo,
Z.
Nowecki,
S.
Im,
M.
Yusof,
C.
Gallardo,
O.
Lipatov,
C.
Barrios,
E.
Holgado,
H.
Iwata,
N.
Masuda,
M.
Otero,
E.
Gokmen,
S.
Loi,
Zifang
Guo,
Jingyi
Zhao,
G.
Aktan,
V.
Karantza,
P.
Schmid,
F.
Luis,
Gomez-Abuin
Gonzalo,
Kaen
Diego,
Kowalwszyn
Ruben,
Molina
Matias,
Varela
Mirta,
B.
Sally,
Begbie
Stephen,
Clingan
Philip,
Loi
Sherene,
S.
Dhanusha,
Gombos
Andrea,
Taylor
Donatienne,
Barrios
Carlos,
Brust
Leandro,
C.
Fabiano,
de
Ruffo,
Hegg
Roberto,
L.
Carvalho,
Lissa
Toniazzi,
Rocha
Odebrecht,
Scalabrini
Orlando,
S.
Felipe,
Cescon
David,
C.
Danielle,
Ferrario
Cristiano,
Song
Xinni,
Yu
Joanne,
Acevedo
Alejandro,
G.
Carlos,
Salas
Claudio,
Sanchez
Cesar,
Yanez
Eduardo,
Gomez
Alvaro,
S.
Jesus,
Holeckova
Petra,
Král
Zdeněk,
Melichar
Bohuslav,
Petrakova
Katarina,
Prausová
Jana,
Glavicic
Vesna,
Jakobsen
Erik,
Jensen
Jeanette,
Linnet
Soren,
Lőrincz
Tamás,
Bonnefoi
Herve,
D.
Isabelle,
Goncalves
Anthony,
Hardy-Bessard
Anne-Claire,
Teixeira
Luis,
Blohmer
Jens-Uwe,
Fasching
Peter,
Forstmeyer
Dirk,
H.
Nadia,
Huober
Jens,
Kaczerowsky
Anna,
Kurbacher
Christian,
L.
Sibylle,
Lueftner
Diana,
P-S
Tjoung-Won,
Schumann
Von,
Wimberger
Pauline,
C.
Louis,
K.
Ava,
N.
Roger,
Arkosy
Peter,
Csőszi
Tibor,
K.
Zsuzsanna,
Landherr
László,
Mahr
Karoly,
Rubovszky
Gábor,
C.
John,
Kelly
Catherine,
O.
Seamus,
Cinieri
Saverio,
DAlessio
Antonietta,
Ricevuto
Enrico,
Aruga
Tomoyuki,
Fujii
Takaaki,
Inoue
Kenichi,
Ishikawa
Takashi,
I.
Yoshinori,
Iwasaki
Tsutomu,
I.
Hiroji,
Kosaka
Yoshimasa,
Matsumoto
Koji,
Miyoshi
Yasuo,
Mukai
Hirofumi,
Nakamura
Seigo,
Niikura
Naoki,
Ohta
Shoichiro,
Osaki
Akihiko,
Sagara
Yasuaki,
Suzuki
Eiji,
Takahashi
Masato,
Tanabe
Yuko,
T.
Kenji,
Tsugawa
Koichiro,
Watanabe
Junichiro,
Yamamoto
Naohito,
Yamamoto
Yutaka,
Yamauchi
Teruo,
Bustam
Anita,
Md
Mastura,
Gomez
Angel,
Juarez
Alejandro,
Martinez
Jorge,
Morales-Vasquez
Flavia,
Reyes
Jessica,
Beelen
Karin,
Tjan-Heijnen
Vivianne,
P.
David,
Chmielowska
Ewa,
Nowakowska-Zajdel
Ewa,
Nowecki
Zbigniew,
Radecka
Barbara,
Streb
Joanna,
Szczylik
Cezary,
Tarnawski
Rafal,
Z.
Bogdan,
Arkhipov
Alexander,
Fadeeva
Natalia,
Lipatov
Oleg,
Meshcheryakov
Andrey,
Moiseyenko
Vladimir,
Mukhametshina
Guzel,
Ahn,
Hee,
Im,
Seock-Ah,
L.
Seok,
Park
Hwa,
park
hee,
Bermejo
Begona,
Cortés
Javier,
Cruz
Josefina,
de
Luis,
Garcia
Jose,
Gion
Maria,
H.
Esther,
Zamora
Esther,
Liu
Chien-Ting,
Liu
Mei-Ching,
Huang
Chiun-Sheng,
Tsao
Chao-Jung,
T.
Ling-Ming,
Arslan
Cagatay,
B.
Gul,
C.
Irfan,
Gokmen
Erhan,
Gunduz
Seyda,
Molinas
Nil,
Ozguroglu
Mustafa,
Ozyilkan
Ozgur,
Y.
Sinan,
Chan
Steve,
Graham
Janine,
MacPherson
Iain,
Schmid
Peter,
Turner
Nicholas,
T.
Mark,
Twelves
Christopher,
Wheatley
Duncan,
Adamchuk
Hryhoriy,
Berzoy
Oleksandr,
Bondarenko
Igor,
Kolesnik
Oleksii,
Kolesnik
Olena,
Komisarenko
Hanna,
Kryzhanivska
Anna,
Leshchenko
Iurii,
Nasonova
Alla,
Otchenash
Natalya,
Ponomarova
Olga,
Rusyn
Andrii,
Shevnya
Sergii,
Shparyk
Yaroslav,
Trukhin
Dmytro,
Ursol
Grygorii,
Vynnychenko
Ihor,
Blau
Sibel,
C.
Madhu,
C.
Michael,
C.
Patrick,
Cole
Scott,
D.
Jennifer,
G.
Keerthi,
H.
Jeffrey,
Hoskins
Kent,
I.
William,
Loutfi
Randa,
Lu
Janice,
M.
Raúl,
M.
Susan,
Nanda
Rita,
Oliff
Ira,
Omene
Coral,
P.
Timothy,
Panwalkar
Amit,
P.
Brian,
Rugo
Hope,
Rybalova
Irina,
Schleider
Michael,
Siegel
Robert,
Simon
Michael,
Stampleman
Laura,
Sumrall
Bradley,
Tsai
Michaela,
Valdes-Albini
Frances
(2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet, 396
-
(
SafonovA
JiangT
BianchiniG
, et al. Immune gene expression is
associated with genomic aberrations in breast cancer.
Cancer Res.
2017;77:3317-3324.28428277)
SafonovA
JiangT
BianchiniG
, et al. Immune gene expression is
associated with genomic aberrations in breast cancer.
Cancer Res.
2017;77:3317-3324.28428277
SafonovA
JiangT
BianchiniG
, et al. Immune gene expression is
associated with genomic aberrations in breast cancer.
Cancer Res.
2017;77:3317-3324.28428277,
SafonovA
JiangT
BianchiniG
, et al. Immune gene expression is
associated with genomic aberrations in breast cancer.
Cancer Res.
2017;77:3317-3324.28428277
-
(
IchiharaE
HaradaD
InoueK
, et al. The impact of body mass
index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with
non-small cell lung cancer. Lung Cancer.
2020;139:140-145.31786476)
IchiharaE
HaradaD
InoueK
, et al. The impact of body mass
index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with
non-small cell lung cancer. Lung Cancer.
2020;139:140-145.31786476
IchiharaE
HaradaD
InoueK
, et al. The impact of body mass
index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with
non-small cell lung cancer. Lung Cancer.
2020;139:140-145.31786476,
IchiharaE
HaradaD
InoueK
, et al. The impact of body mass
index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with
non-small cell lung cancer. Lung Cancer.
2020;139:140-145.31786476
-
E.
Nolan,
P.
Savas,
A.
Policheni,
P.
Darcy,
F.
Vaillant,
Christopher
Mintoff,
S.
Dushyanthen,
Mariam
Mansour,
J.
Pang,
S.
Fox,
C.
Perou,
J.
Visvader,
D.
Gray,
S.
Loi,
G.
Lindeman
(2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Science Translational Medicine, 9
-
C.
Denkert,
G.
Minckwitz,
J.
Brase,
B.
Sinn,
S.
Gade,
R.
Kronenwett,
B.
Pfitzner,
C.
Salat,
S.
Loi,
W.
Schmitt,
C.
Schem,
K.
Fisch,
S.
Darb-Esfahani,
K.
Mehta,
C.
Sotiriou,
S.
Wienert,
P.
Klare,
F.
André,
F.
Klauschen,
J.
Blohmer,
K.
Krappmann,
Marcus
Schmidt,
H.
Tesch,
S.
Kümmel,
P.
Sinn,
C.
Jackisch,
M.
Dietel,
T.
Reimer,
M.
Untch,
S.
Loibl
(2015)
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 9
-
(
PapadimitriouM
MountziosG
PapadimitriouCA.
The role of PARP inhibition in triple-negative breast cancer:
unraveling the wide spectrum of synthetic lethality.
Cancer Treat Rev.
2018;67:34-44.29753961)
PapadimitriouM
MountziosG
PapadimitriouCA.
The role of PARP inhibition in triple-negative breast cancer:
unraveling the wide spectrum of synthetic lethality.
Cancer Treat Rev.
2018;67:34-44.29753961
PapadimitriouM
MountziosG
PapadimitriouCA.
The role of PARP inhibition in triple-negative breast cancer:
unraveling the wide spectrum of synthetic lethality.
Cancer Treat Rev.
2018;67:34-44.29753961,
PapadimitriouM
MountziosG
PapadimitriouCA.
The role of PARP inhibition in triple-negative breast cancer:
unraveling the wide spectrum of synthetic lethality.
Cancer Treat Rev.
2018;67:34-44.29753961
-
(
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in
metastatic triple-negative breast cancer. N Engl J
Med.
2021;384:1529-1541.33882206)
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in
metastatic triple-negative breast cancer. N Engl J
Med.
2021;384:1529-1541.33882206
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in
metastatic triple-negative breast cancer. N Engl J
Med.
2021;384:1529-1541.33882206,
BardiaA
HurvitzSA
TolaneySM
, et al. Sacituzumab govitecan in
metastatic triple-negative breast cancer. N Engl J
Med.
2021;384:1529-1541.33882206
-
(
AndtbackaRH
RossM
PuzanovI
, et al. Patterns of clinical
response with talimogene laherparepvec (T-VEC) in patients with melanoma
treated in the OPTiM phase III clinical trial. Ann
Surg Oncol.
2016;23:4169-4177.27342831)
AndtbackaRH
RossM
PuzanovI
, et al. Patterns of clinical
response with talimogene laherparepvec (T-VEC) in patients with melanoma
treated in the OPTiM phase III clinical trial. Ann
Surg Oncol.
2016;23:4169-4177.27342831
AndtbackaRH
RossM
PuzanovI
, et al. Patterns of clinical
response with talimogene laherparepvec (T-VEC) in patients with melanoma
treated in the OPTiM phase III clinical trial. Ann
Surg Oncol.
2016;23:4169-4177.27342831,
AndtbackaRH
RossM
PuzanovI
, et al. Patterns of clinical
response with talimogene laherparepvec (T-VEC) in patients with melanoma
treated in the OPTiM phase III clinical trial. Ann
Surg Oncol.
2016;23:4169-4177.27342831
-
A.
Garrido-Castro,
T.
Keenan,
Tianyu
Li,
Paulina
Lange,
Catherine
Callahan,
Jennifer
Guerriero,
N.
Tayob,
L.
Anderson,
C.
Yam,
B.
Daniel,
L.
Carey,
R.
Nanda,
E.
Winer,
E.
Mittendorf,
S.
Tolaney
(2021)
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
Journal of Clinical Oncology
-
Gang
Chen,
L.
Emens
(2013)
Chemoimmunotherapy: reengineering tumor immunity
Cancer Immunology, Immunotherapy, 62
-
(
LiuZ
LiM
JiangZ
WangX.
A comprehensive immunologic portrait of triple-negative breast
cancer. Transl Oncol.
2018;11:311-329.29413765)
LiuZ
LiM
JiangZ
WangX.
A comprehensive immunologic portrait of triple-negative breast
cancer. Transl Oncol.
2018;11:311-329.29413765
LiuZ
LiM
JiangZ
WangX.
A comprehensive immunologic portrait of triple-negative breast
cancer. Transl Oncol.
2018;11:311-329.29413765,
LiuZ
LiM
JiangZ
WangX.
A comprehensive immunologic portrait of triple-negative breast
cancer. Transl Oncol.
2018;11:311-329.29413765
-
Le DT,
Uram JN,
Wang H,
et al
(2015)
PD-1 blockade in tumors with mismatch-repair deficiency
N Engl J Med., 372
-
(
O’BrienGC
CahillRA
Bouchier-HayesDJ
RedmondHP.
Co-immunotherapy with interleukin-2 and taurolidine for
progressive metastatic melanoma. Ir J Med
Sci.
2006;175:10-14.)
O’BrienGC
CahillRA
Bouchier-HayesDJ
RedmondHP.
Co-immunotherapy with interleukin-2 and taurolidine for
progressive metastatic melanoma. Ir J Med
Sci.
2006;175:10-14.
O’BrienGC
CahillRA
Bouchier-HayesDJ
RedmondHP.
Co-immunotherapy with interleukin-2 and taurolidine for
progressive metastatic melanoma. Ir J Med
Sci.
2006;175:10-14.,
O’BrienGC
CahillRA
Bouchier-HayesDJ
RedmondHP.
Co-immunotherapy with interleukin-2 and taurolidine for
progressive metastatic melanoma. Ir J Med
Sci.
2006;175:10-14.
-
Sarah
Alaiwi,
W.
Xie,
A.
Nassar,
Shaan
Dudani,
D.
Martini,
Z.
Bakouny,
J.
Steinharter,
P.
Nuzzo,
R.
Flippot,
N.
Martinez-Chanza,
Xiao
Wei,
B.
McGregor,
M.
Kaymakcalan,
D.
Heng,
M.
Bilen,
T.
Choueiri,
L.
Harshman
(2020)
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
Journal for Immunotherapy of Cancer, 8
-
(
DillEA
GruAA
AtkinsKA
, et al. PD-L1 expression and
intratumoral heterogeneity across breast cancer subtypes and stages: an
assessment of 245 primary and 40 metastatic tumors.
Am J Surg Pathol.
2017;41:334-342.28195880)
DillEA
GruAA
AtkinsKA
, et al. PD-L1 expression and
intratumoral heterogeneity across breast cancer subtypes and stages: an
assessment of 245 primary and 40 metastatic tumors.
Am J Surg Pathol.
2017;41:334-342.28195880
DillEA
GruAA
AtkinsKA
, et al. PD-L1 expression and
intratumoral heterogeneity across breast cancer subtypes and stages: an
assessment of 245 primary and 40 metastatic tumors.
Am J Surg Pathol.
2017;41:334-342.28195880,
DillEA
GruAA
AtkinsKA
, et al. PD-L1 expression and
intratumoral heterogeneity across breast cancer subtypes and stages: an
assessment of 245 primary and 40 metastatic tumors.
Am J Surg Pathol.
2017;41:334-342.28195880
-
J.
Wolchok,
H.
Kluger,
M.
Callahan,
M.
Postow,
N.
Rizvi,
A.
Lesokhin,
N.
Segal,
C.
Ariyan,
R.
Gordon,
Kathleen
Reed,
M.
Burke,
A.
Caldwell,
S.
Kronenberg,
B.
Agunwamba,
Xiaoling
Zhang,
I.
Lowy,
H.
Inzunza,
W.
Feely,
C.
Horak,
Q.
Hong,
A.
Korman,
J.
Wigginton,
A.
Gupta,
M.
Sznol
(2013)
Nivolumab plus ipilimumab in advanced melanoma.
The New England journal of medicine, 369 2
-
Xiangli
Ding,
Qiaochao
Chen,
Zhao
Yang,
Jun
Li,
Hui
Zhan,
Nihong
Lu,
Min
Chen,
Yanlong
Yang,
Jiansong
Wang,
Delin
Yang
(2019)
Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
Cancer Management and Research, 11
-
(
JuliaEP
AmanteA
PampenaMB
MordohJ
LevyEM.
Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor,
triggers NK Cell-mediated cytotoxicity and cytokine production against
triple negative breast cancer cells. Front
Immunol.
2018;9:2140.)
JuliaEP
AmanteA
PampenaMB
MordohJ
LevyEM.
Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor,
triggers NK Cell-mediated cytotoxicity and cytokine production against
triple negative breast cancer cells. Front
Immunol.
2018;9:2140.
JuliaEP
AmanteA
PampenaMB
MordohJ
LevyEM.
Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor,
triggers NK Cell-mediated cytotoxicity and cytokine production against
triple negative breast cancer cells. Front
Immunol.
2018;9:2140.,
JuliaEP
AmanteA
PampenaMB
MordohJ
LevyEM.
Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor,
triggers NK Cell-mediated cytotoxicity and cytokine production against
triple negative breast cancer cells. Front
Immunol.
2018;9:2140.
-
(
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA Cancer J
Clin.
2019;69:7-34.30620402)
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA Cancer J
Clin.
2019;69:7-34.30620402
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA Cancer J
Clin.
2019;69:7-34.30620402,
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA Cancer J
Clin.
2019;69:7-34.30620402
-
P.
Schmid,
H.
Rugo,
S.
Adams,
A.
Schneeweiss,
C.
Barrios,
H.
Iwata,
V.
Diéras,
V.
Henschel,
L.
Molinero,
S.
Chui,
V.
Maiya,
A.
Husain,
E.
Winer,
S.
Loi,
L.
Emens
(2019)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology
-
(
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus
chemotherapy versus placebo plus chemotherapy for previously untreated
locally recurrent inoperable or metastatic triple-negative breast cancer
(KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3
clinical trial. Lancet.
2020;396:1817-1828.33278935)
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus
chemotherapy versus placebo plus chemotherapy for previously untreated
locally recurrent inoperable or metastatic triple-negative breast cancer
(KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3
clinical trial. Lancet.
2020;396:1817-1828.33278935
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus
chemotherapy versus placebo plus chemotherapy for previously untreated
locally recurrent inoperable or metastatic triple-negative breast cancer
(KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3
clinical trial. Lancet.
2020;396:1817-1828.33278935,
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus
chemotherapy versus placebo plus chemotherapy for previously untreated
locally recurrent inoperable or metastatic triple-negative breast cancer
(KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3
clinical trial. Lancet.
2020;396:1817-1828.33278935
-
T.
Schumacher,
R.
Schreiber
(2015)
Neoantigens in cancer immunotherapy
Science, 348
-
Lindsey
Torre,
F.
Bray,
R.
Siegel,
J.
Ferlay,
J.
Lortet-Tieulent,
A.
Jemal
(2015)
Global cancer statistics, 2012
CA: A Cancer Journal for Clinicians, 65
-
S.
Popat,
R.
Hubner,
R.
Houlston
(2005)
Systematic review of microsatellite instability and colorectal cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 3
-
(
SalehR
TahaRZ
Sasidharan NairV
AlajezNM
ElkordE.
PD-L1 blockade by atezolizumab downregulates signaling pathways
associated with tumor growth, metastasis, and hypoxia in human triple
negative breast cancer. Cancers (Basel).
2019;11:1050.)
SalehR
TahaRZ
Sasidharan NairV
AlajezNM
ElkordE.
PD-L1 blockade by atezolizumab downregulates signaling pathways
associated with tumor growth, metastasis, and hypoxia in human triple
negative breast cancer. Cancers (Basel).
2019;11:1050.
SalehR
TahaRZ
Sasidharan NairV
AlajezNM
ElkordE.
PD-L1 blockade by atezolizumab downregulates signaling pathways
associated with tumor growth, metastasis, and hypoxia in human triple
negative breast cancer. Cancers (Basel).
2019;11:1050.,
SalehR
TahaRZ
Sasidharan NairV
AlajezNM
ElkordE.
PD-L1 blockade by atezolizumab downregulates signaling pathways
associated with tumor growth, metastasis, and hypoxia in human triple
negative breast cancer. Cancers (Basel).
2019;11:1050.
-
F.
Fallarino,
P.
Fields,
T.
Gajewski
(1998)
B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28
The Journal of Experimental Medicine, 188
-
(
DentR
TrudeauM
PritchardKI
, et al. Triple-negative breast
cancer: clinical features and patterns of recurrence.
Clin Cancer Res.
2007;13:4429-4434.17671126)
DentR
TrudeauM
PritchardKI
, et al. Triple-negative breast
cancer: clinical features and patterns of recurrence.
Clin Cancer Res.
2007;13:4429-4434.17671126
DentR
TrudeauM
PritchardKI
, et al. Triple-negative breast
cancer: clinical features and patterns of recurrence.
Clin Cancer Res.
2007;13:4429-4434.17671126,
DentR
TrudeauM
PritchardKI
, et al. Triple-negative breast
cancer: clinical features and patterns of recurrence.
Clin Cancer Res.
2007;13:4429-4434.17671126
-
Jean-Marie
Michot,
C.
Bigenwald,
S.
Champiat,
M.
Collins,
F.
Carbonnel,
S.
Postel-Vinay,
A.
Berdelou,
A.
Varga,
R.
Bahleda,
A.
Hollebecque,
C.
Massard,
A.
Fuerea,
V.
Ribrag,
A.
Gazzah,
J.
Armand,
N.
Amellal,
E.
Angevin,
N.
Noel,
C.
Boutros,
C.
Mateus,
C.
Robert,
J.
Soria,
A.
Marabelle,
O.
Lambotte
(2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
European journal of cancer, 54
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC,
https://clinicaltrials
gov/ct2/show/study/NCT04468061
-
(
BonvalotS
GronchiA
Le PechouxC
, et al. STRASS (EORTC 62092): a
phase III randomized study of preoperative radiotherapy plus surgery versus
surgery alone for patients with retroperitoneal sarcoma.
J Clin Oncol.
2019;37:11001.)
BonvalotS
GronchiA
Le PechouxC
, et al. STRASS (EORTC 62092): a
phase III randomized study of preoperative radiotherapy plus surgery versus
surgery alone for patients with retroperitoneal sarcoma.
J Clin Oncol.
2019;37:11001.
BonvalotS
GronchiA
Le PechouxC
, et al. STRASS (EORTC 62092): a
phase III randomized study of preoperative radiotherapy plus surgery versus
surgery alone for patients with retroperitoneal sarcoma.
J Clin Oncol.
2019;37:11001.,
BonvalotS
GronchiA
Le PechouxC
, et al. STRASS (EORTC 62092): a
phase III randomized study of preoperative radiotherapy plus surgery versus
surgery alone for patients with retroperitoneal sarcoma.
J Clin Oncol.
2019;37:11001.
-
(
MilesDW
GligorovJ
AndreF
, et al. LBA15 Primary results from
IMpassion131, a double-blind placebo-controlled randomised phase III trial
of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable
locally advanced/metastatic triple-negative breast cancer
(mTNBC). Ann Oncol.
2020;31:S1147-S1148.)
MilesDW
GligorovJ
AndreF
, et al. LBA15 Primary results from
IMpassion131, a double-blind placebo-controlled randomised phase III trial
of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable
locally advanced/metastatic triple-negative breast cancer
(mTNBC). Ann Oncol.
2020;31:S1147-S1148.
MilesDW
GligorovJ
AndreF
, et al. LBA15 Primary results from
IMpassion131, a double-blind placebo-controlled randomised phase III trial
of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable
locally advanced/metastatic triple-negative breast cancer
(mTNBC). Ann Oncol.
2020;31:S1147-S1148.,
MilesDW
GligorovJ
AndreF
, et al. LBA15 Primary results from
IMpassion131, a double-blind placebo-controlled randomised phase III trial
of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable
locally advanced/metastatic triple-negative breast cancer
(mTNBC). Ann Oncol.
2020;31:S1147-S1148.
-
fda-approves-pembrolizumab-highrisk-early-stage-triple-negative-breast-cancer?utm_medium=email&utm_ source=govdelivery
-
(
SugieT.
Immunotherapy for metastatic breast cancer.
Chin Clin Oncol.
2018;7:28.30056730)
SugieT.
Immunotherapy for metastatic breast cancer.
Chin Clin Oncol.
2018;7:28.30056730
SugieT.
Immunotherapy for metastatic breast cancer.
Chin Clin Oncol.
2018;7:28.30056730,
SugieT.
Immunotherapy for metastatic breast cancer.
Chin Clin Oncol.
2018;7:28.30056730
-
T.
Sørlie,
R.
Tibshirani,
Joel
Parker,
T.
Hastie,
J.
Marron,
A.
Nobel,
Shibing
Deng,
H.
Johnsen,
Robert
Pesich,
S.
Geisler,
J.
Demeter,
C.
Perou,
P.
Lønning,
P.
Brown,
A.
Børresen-Dale,
D.
Botstein
(2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
Proceedings of the National Academy of Sciences of the United States of America, 100
-
(
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of
breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA.
2003;100:8418-8423.12829800)
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of
breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA.
2003;100:8418-8423.12829800
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of
breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA.
2003;100:8418-8423.12829800,
SorlieT
TibshiraniR
ParkerJ
, et al. Repeated observation of
breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci USA.
2003;100:8418-8423.12829800
-
(
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or
nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate
067): 4-year outcomes of a multicentre, randomised, phase 3
trial. Lancet Oncol.
2018;19:1480-1492.30361170)
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or
nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate
067): 4-year outcomes of a multicentre, randomised, phase 3
trial. Lancet Oncol.
2018;19:1480-1492.30361170
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or
nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate
067): 4-year outcomes of a multicentre, randomised, phase 3
trial. Lancet Oncol.
2018;19:1480-1492.30361170,
HodiFS
Chiarion-SileniV
GonzalezR
, et al. Nivolumab plus ipilimumab or
nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate
067): 4-year outcomes of a multicentre, randomised, phase 3
trial. Lancet Oncol.
2018;19:1480-1492.30361170
-
L.
Molinero,
Yijin
Li,
Ching-Wei
Chang,
S.
Maund,
M.
Berg,
J.
Harrison,
M.
Fassò,
C.
O'Hear,
P.
Hegde,
L.
Emens
(2019)
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
Journal for Immunotherapy of Cancer, 7
-
(
NangiaC
Soon-ShiongP
RabizadehS
, et al. 358P—complete responses in
patients with second-line or greater metastatic triple negative breast
cancer (TNBC) following first-in-human immunotherapy combining NK and T cell
activation with off-the-shelf high-affinity CD16 NK cell line
(haNK). Ann Oncol.
2019;30:v130.)
NangiaC
Soon-ShiongP
RabizadehS
, et al. 358P—complete responses in
patients with second-line or greater metastatic triple negative breast
cancer (TNBC) following first-in-human immunotherapy combining NK and T cell
activation with off-the-shelf high-affinity CD16 NK cell line
(haNK). Ann Oncol.
2019;30:v130.
NangiaC
Soon-ShiongP
RabizadehS
, et al. 358P—complete responses in
patients with second-line or greater metastatic triple negative breast
cancer (TNBC) following first-in-human immunotherapy combining NK and T cell
activation with off-the-shelf high-affinity CD16 NK cell line
(haNK). Ann Oncol.
2019;30:v130.,
NangiaC
Soon-ShiongP
RabizadehS
, et al. 358P—complete responses in
patients with second-line or greater metastatic triple negative breast
cancer (TNBC) following first-in-human immunotherapy combining NK and T cell
activation with off-the-shelf high-affinity CD16 NK cell line
(haNK). Ann Oncol.
2019;30:v130.
-
S.
Adams,
R.
Gray,
S.
Demaria,
L.
Goldstein,
E.
Perez,
L.
Shulman,
S.
Martino,
Molin
Wang,
V.
Jones,
T.
Saphner,
A.
Wolff,
W.
Wood,
N.
Davidson,
G.
Sledge,
J.
Sparano,
S.
Badve
(2014)
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 27
-
L.
Emens,
G.
Middleton
(2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Cancer Immunology Research, 3
-
(
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of
niraparib combined with pembrolizumab for treatment of advanced or
metastatic triple-negative breast cancer. JAMA
Oncol.
2019;5:1132-1140.31194225)
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of
niraparib combined with pembrolizumab for treatment of advanced or
metastatic triple-negative breast cancer. JAMA
Oncol.
2019;5:1132-1140.31194225
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of
niraparib combined with pembrolizumab for treatment of advanced or
metastatic triple-negative breast cancer. JAMA
Oncol.
2019;5:1132-1140.31194225,
VinayakS
TolaneySM
SchwartzbergL
, et al. Open-label clinical trial of
niraparib combined with pembrolizumab for treatment of advanced or
metastatic triple-negative breast cancer. JAMA
Oncol.
2019;5:1132-1140.31194225
-
L.
Brown,
S.
Loi
(2021)
Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update
The Breast : Official Journal of the European Society of Mastology, 62
-
S.
Loi,
S.
Loi,
S.
Michiels,
S.
Michiels,
R.
Salgado,
N.
Sirtaine,
V.
Jose,
D.
Fumagalli,
P.
Kellokumpu-Lehtinen,
P.
Bono,
V.
Kataja,
C.
Desmedt,
M.
Piccart,
S.
Loibl,
C.
Denkert,
M.
Smyth,
H.
Joensuu,
C.
Sotiriou
(2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
-
Hiro
Sato,
A.
Niimi,
Takaaki
Yasuhara,
Tiara
Permata,
Yoshihiko
Hagiwara,
Mayu
Isono,
E.
Nuryadi,
Ryota
Sekine,
T.
Oike,
Sangeeta
Kakoti,
Y.
Yoshimoto,
K.
Held,
Yoshiyuki
Suzuki,
K.
Kono,
K.
Miyagawa,
T.
Nakano,
A.
Shibata
(2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Nature Communications, 8
-
Indrė
Januškevičienė,
V.
Petrikaitė
(2019)
Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations.
Life sciences
-
B.
Heppner,
S.
Loibl,
C.
Denkert
(2016)
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer
Breast Care, 11
-
S.
Loibl,
M.
Untch,
N.
Burchardi,
J.
Huober,
B.
Sinn,
J.
Blohmer,
E.
Grischke,
J.
Furlanetto,
H.
Tesch,
C.
Hanusch,
K.
Engels,
M.
Rezai,
C.
Jackisch,
W.
Schmitt,
G.
Minckwitz,
Jörg
Thomalla,
S.
Kümmel,
B.
Rautenberg,
P.
Fasching,
K.
Weber,
K.
Rhiem,
C.
Denkert,
A.
Schneeweiss
(2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
Annals of oncology : official journal of the European Society for Medical Oncology
-
(
GhiringhelliF
MenardC
PuigPE
, et al. Metronomic cyclophosphamide
regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and
NK effector functions in end stage cancer patients.
Cancer Immunol Immunother.
2007;56:641-648.16960692)
GhiringhelliF
MenardC
PuigPE
, et al. Metronomic cyclophosphamide
regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and
NK effector functions in end stage cancer patients.
Cancer Immunol Immunother.
2007;56:641-648.16960692
GhiringhelliF
MenardC
PuigPE
, et al. Metronomic cyclophosphamide
regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and
NK effector functions in end stage cancer patients.
Cancer Immunol Immunother.
2007;56:641-648.16960692,
GhiringhelliF
MenardC
PuigPE
, et al. Metronomic cyclophosphamide
regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and
NK effector functions in end stage cancer patients.
Cancer Immunol Immunother.
2007;56:641-648.16960692
-
(
FallarinoF
FieldsPE
GajewskiTF.
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T
cell activation in the absence of CD28. J Exp
Med.
1998;188:205-210.9653097)
FallarinoF
FieldsPE
GajewskiTF.
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T
cell activation in the absence of CD28. J Exp
Med.
1998;188:205-210.9653097
FallarinoF
FieldsPE
GajewskiTF.
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T
cell activation in the absence of CD28. J Exp
Med.
1998;188:205-210.9653097,
FallarinoF
FieldsPE
GajewskiTF.
B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T
cell activation in the absence of CD28. J Exp
Med.
1998;188:205-210.9653097
-
A.
Bardia,
S.
Hurvitz,
S.
Tolaney,
D.
Loirat,
K.
Punie,
Mafalda
Oliveira,
A.
Brufsky,
S.
Sardesai,
K.
Kalinsky,
A.
Zelnak,
R.
Weaver,
T.
Traina,
F.
Dalenc,
P.
Aftimos,
F.
Lynce,
S.
Diab,
J.
Cortés,
J.
O’Shaughnessy,
V.
Diéras,
C.
Ferrario,
P.
Schmid,
L.
Carey,
L.
Gianni,
M.
Piccart,
S.
Loibl,
D.
Goldenberg,
Q.
Hong,
M.
Olivo,
L.
Itri,
H.
Rugo
(2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
The New England journal of medicine, 384 16
-
E.
Masteller,
E.
Chuang,
Alan
Mullen,
S.
Reiner,
C.
Thompson
(2000)
Structural Analysis of CTLA-4 Function In Vivo1
The Journal of Immunology, 164
-
(
DenkertC
von MinckwitzG
BraseJC
, et al. Tumor-infiltrating
lymphocytes and response to neoadjuvant chemotherapy with or without
carboplatin in human epidermal growth factor receptor 2-positive and
triple-negative primary breast cancers. J Clin
Oncol.
2015;33:983-991.25534375)
DenkertC
von MinckwitzG
BraseJC
, et al. Tumor-infiltrating
lymphocytes and response to neoadjuvant chemotherapy with or without
carboplatin in human epidermal growth factor receptor 2-positive and
triple-negative primary breast cancers. J Clin
Oncol.
2015;33:983-991.25534375
DenkertC
von MinckwitzG
BraseJC
, et al. Tumor-infiltrating
lymphocytes and response to neoadjuvant chemotherapy with or without
carboplatin in human epidermal growth factor receptor 2-positive and
triple-negative primary breast cancers. J Clin
Oncol.
2015;33:983-991.25534375,
DenkertC
von MinckwitzG
BraseJC
, et al. Tumor-infiltrating
lymphocytes and response to neoadjuvant chemotherapy with or without
carboplatin in human epidermal growth factor receptor 2-positive and
triple-negative primary breast cancers. J Clin
Oncol.
2015;33:983-991.25534375
-
(
Garrido-CastroAC
KeenanTE
LiT
, et al. Saci-IO TNBC: randomized
phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in
PD-L1–metastatic triple-negative breast cancer (mTNBC).
J Clin Oncol.
2021;39:TPS1106.)
Garrido-CastroAC
KeenanTE
LiT
, et al. Saci-IO TNBC: randomized
phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in
PD-L1–metastatic triple-negative breast cancer (mTNBC).
J Clin Oncol.
2021;39:TPS1106.
Garrido-CastroAC
KeenanTE
LiT
, et al. Saci-IO TNBC: randomized
phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in
PD-L1–metastatic triple-negative breast cancer (mTNBC).
J Clin Oncol.
2021;39:TPS1106.,
Garrido-CastroAC
KeenanTE
LiT
, et al. Saci-IO TNBC: randomized
phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in
PD-L1–metastatic triple-negative breast cancer (mTNBC).
J Clin Oncol.
2021;39:TPS1106.
-
M.
Bonotto,
L.
Gerratana,
E.
Poletto,
P.
Driol,
M.
Giangreco,
S.
Russo,
A.
Minisini,
C.
Andreetta,
M.
Mansutti,
F.
Pisa,
G.
Fasola,
F.
Puglisi
(2014)
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
The oncologist, 19 6
-
Christel
Devaud,
Liza
John,
J.
Westwood,
P.
Darcy,
M.
Kershaw
(2013)
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
Oncoimmunology, 2
-
(
ThomasA
RouthED
PullikuthA
, et al. Tumor mutational burden is a
determinant of immune-mediated survival in breast cancer.
Oncoimmunology.
2018;7:e1490854.30386679)
ThomasA
RouthED
PullikuthA
, et al. Tumor mutational burden is a
determinant of immune-mediated survival in breast cancer.
Oncoimmunology.
2018;7:e1490854.30386679
ThomasA
RouthED
PullikuthA
, et al. Tumor mutational burden is a
determinant of immune-mediated survival in breast cancer.
Oncoimmunology.
2018;7:e1490854.30386679,
ThomasA
RouthED
PullikuthA
, et al. Tumor mutational burden is a
determinant of immune-mediated survival in breast cancer.
Oncoimmunology.
2018;7:e1490854.30386679
-
A.
Snyder,
V.
Makarov,
T.
Merghoub,
Jianda
Yuan,
J.
Zaretsky,
A.
Desrichard,
L.
Walsh,
M.
Postow,
P.
Wong,
Teresa
Ho,
T.
Hollmann,
Cameron
Bruggeman,
Kasthuri
Kannan,
Yanyun
Li,
Ceyhan
Elipenahli,
Cailian
Liu,
C.
Harbison,
Lisu
Wang,
A.
Ribas,
J.
Wolchok,
T.
Chan
(2014)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
The New England journal of medicine, 371 23
-
M.
Keir,
M.
Butte,
G.
Freeman,
A.
Sharpe
(2008)
PD-1 and its ligands in tolerance and immunity.
Annual review of immunology, 26
-
K.
Bauer,
Monica
Brown,
R.
Cress,
C.
Parise,
V.
Caggiano
(2007)
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype
Cancer, 109
-
(
LoiblS
SchneeweissA
HuoberJB
, et al. Durvalumab improves
long-term outcome in TNBC: results from the phase II randomized GeparNUEVO
study investigating neodjuvant durvalumab in addition to an
anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative
breast cancer (TNBC). J Clin Oncol.
2021;39:506-506.)
LoiblS
SchneeweissA
HuoberJB
, et al. Durvalumab improves
long-term outcome in TNBC: results from the phase II randomized GeparNUEVO
study investigating neodjuvant durvalumab in addition to an
anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative
breast cancer (TNBC). J Clin Oncol.
2021;39:506-506.
LoiblS
SchneeweissA
HuoberJB
, et al. Durvalumab improves
long-term outcome in TNBC: results from the phase II randomized GeparNUEVO
study investigating neodjuvant durvalumab in addition to an
anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative
breast cancer (TNBC). J Clin Oncol.
2021;39:506-506.,
LoiblS
SchneeweissA
HuoberJB
, et al. Durvalumab improves
long-term outcome in TNBC: results from the phase II randomized GeparNUEVO
study investigating neodjuvant durvalumab in addition to an
anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative
breast cancer (TNBC). J Clin Oncol.
2021;39:506-506.
-
L.
Carey,
C.
Perou,
C.
Livasy,
L.
Dressler,
D.
Cowan,
K.
Conway,
G.
Karaca,
M.
Troester,
C.
Tse,
S.
Edmiston,
Sandra
Deming,
J.
Geradts,
M.
Cheang,
T.
Nielsen,
P.
Moorman,
H.
Earp,
R.
Millikan
(2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
JAMA, 295 21
-
Matthew Hellmann HJW
Management of advanced non-small cell lung cancer lacking a driver mutation: immunotherapy
-
E.
Ferreira,
R.
Brianese,
Renan
Almeida,
R.
Drummond,
J.
Souza,
I.
Silva,
S.
Souza,
D.
Carraro
(2019)
Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
Translational Oncology, 12
-
(
OzakiY
MukoharaT
TsurutaniJ
, et al. Abstract PD1-03: a
multicenter phase II study evaluating the efficacy of nivolumab plus
paclitaxel plus bevacizumab triple-combination therapy as a first-line
treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B
NEWBEAT trial. Cancer Res.
2020;80:PD1-03.)
OzakiY
MukoharaT
TsurutaniJ
, et al. Abstract PD1-03: a
multicenter phase II study evaluating the efficacy of nivolumab plus
paclitaxel plus bevacizumab triple-combination therapy as a first-line
treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B
NEWBEAT trial. Cancer Res.
2020;80:PD1-03.
OzakiY
MukoharaT
TsurutaniJ
, et al. Abstract PD1-03: a
multicenter phase II study evaluating the efficacy of nivolumab plus
paclitaxel plus bevacizumab triple-combination therapy as a first-line
treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B
NEWBEAT trial. Cancer Res.
2020;80:PD1-03.,
OzakiY
MukoharaT
TsurutaniJ
, et al. Abstract PD1-03: a
multicenter phase II study evaluating the efficacy of nivolumab plus
paclitaxel plus bevacizumab triple-combination therapy as a first-line
treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B
NEWBEAT trial. Cancer Res.
2020;80:PD1-03.
-
(
AudehMW
DadmaneshF
YearleyJ.
Abstract P4-04-01: PDL-1 expression in primary breast cancers
with germline mutations in BRCA 1 and 2. Cancer
Res.
2016;76:P4-04-01.)
AudehMW
DadmaneshF
YearleyJ.
Abstract P4-04-01: PDL-1 expression in primary breast cancers
with germline mutations in BRCA 1 and 2. Cancer
Res.
2016;76:P4-04-01.
AudehMW
DadmaneshF
YearleyJ.
Abstract P4-04-01: PDL-1 expression in primary breast cancers
with germline mutations in BRCA 1 and 2. Cancer
Res.
2016;76:P4-04-01.,
AudehMW
DadmaneshF
YearleyJ.
Abstract P4-04-01: PDL-1 expression in primary breast cancers
with germline mutations in BRCA 1 and 2. Cancer
Res.
2016;76:P4-04-01.
-
S.
Loi,
N.
Sirtaine,
F.
Piette,
R.
Salgado,
G.
Viale,
F.
Eenoo,
G.
Rouas,
P.
Francis,
J.
Crown,
E.
Hitre,
E.
Azambuja,
E.
Quinaux,
A.
Leo,
S.
Michiels,
M.
Piccart,
C.
Sotiriou
(2013)
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 7
-
(
RugoHS
LoiS
AdamsS
, et al. PD-L1 immunohistochemistry
assay comparison in atezolizumab plus nab-paclitaxel-treated advanced
triple-negative breast cancer. J Natl Cancer
Inst.
2021;113:1733-1743.)
RugoHS
LoiS
AdamsS
, et al. PD-L1 immunohistochemistry
assay comparison in atezolizumab plus nab-paclitaxel-treated advanced
triple-negative breast cancer. J Natl Cancer
Inst.
2021;113:1733-1743.
RugoHS
LoiS
AdamsS
, et al. PD-L1 immunohistochemistry
assay comparison in atezolizumab plus nab-paclitaxel-treated advanced
triple-negative breast cancer. J Natl Cancer
Inst.
2021;113:1733-1743.,
RugoHS
LoiS
AdamsS
, et al. PD-L1 immunohistochemistry
assay comparison in atezolizumab plus nab-paclitaxel-treated advanced
triple-negative breast cancer. J Natl Cancer
Inst.
2021;113:1733-1743.
-
Anna
Capasso,
J.
Lang,
T.
Pitts,
Kimberly
Jordan,
Christopher
Lieu,
S.
Davis,
Jennifer
Diamond,
S.
Kopetz,
J.
Barbee,
J.
Peterson,
Brian
Freed,
Betelehem
Yacob,
S.
Bagby,
W.
Messersmith,
J.
Slansky,
Roberta
Pelanda,
S.
Eckhardt
(2019)
Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts
Journal for Immunotherapy of Cancer, 7
-
Cesar
Santa-Maria,
T.
Kato,
Jae-Hyun
Park,
K.
Kiyotani,
A.
Rademaker,
Ami
Shah,
L.
Gross,
Luis
Blanco,
Sarika
Jain,
Lisa
Flaum,
C.
Tellez,
R.
Stein,
Regina
Uthe,
W.
Gradishar,
M.
Cristofanilli,
Yusuke
Nakamura,
F.
Giles
(2018)
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
Oncotarget, 9
-
E.
Mittendorf,
Hong
Zhang,
C.
Barrios,
S.
Saji,
K.
Jung,
R.
Hegg,
A.
Koehler,
J.
Sohn,
H.
Iwata,
M.
Telli,
C.
Ferrario,
K.
Punie,
F.
Penault-Llorca,
Shilpen
Patel,
A.
Duc,
M.
Liste-Hermoso,
V.
Maiya,
L.
Molinero,
S.
Chui,
N.
Harbeck
(2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
The Lancet, 396
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
Yi
Xiao,
D.
Ma,
Shen
Zhao,
C.
Suo,
Jinxiu
Shi,
Meng-zhu
Xue,
M.
Ruan,
Hai
Wang,
Jingjing
Zhao,
Qin
Li,
Peng
Wang,
Leming
Shi,
Wen-Tao
Yang,
Wei
Huang,
Xin
Hu,
Keda
Yu,
Shenglin
Huang,
F.
Bertucci,
Yizhou
Jiang,
Z.
Shao
(2019)
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Clinical Cancer Research, 25
-
A.
Alistar,
J.
Chou,
S.
Nagalla,
M.
Black,
R.
D'Agostino,
L.
Miller
(2014)
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
Genome Medicine, 6
-
(
ZingoniA
FiondaC
BorrelliC
CippitelliM
SantoniA
SorianiA.
Natural killer cell response to chemotherapy-stressed cancer
cells: role in tumor immunosurveillance. Front
Immunol.
2017;8:1194.)
ZingoniA
FiondaC
BorrelliC
CippitelliM
SantoniA
SorianiA.
Natural killer cell response to chemotherapy-stressed cancer
cells: role in tumor immunosurveillance. Front
Immunol.
2017;8:1194.
ZingoniA
FiondaC
BorrelliC
CippitelliM
SantoniA
SorianiA.
Natural killer cell response to chemotherapy-stressed cancer
cells: role in tumor immunosurveillance. Front
Immunol.
2017;8:1194.,
ZingoniA
FiondaC
BorrelliC
CippitelliM
SantoniA
SorianiA.
Natural killer cell response to chemotherapy-stressed cancer
cells: role in tumor immunosurveillance. Front
Immunol.
2017;8:1194.
-
(
CardosoF
KyriakidesS
OhnoS
, et al. Early breast cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol.
2019;30:1194-1220.31161190)
CardosoF
KyriakidesS
OhnoS
, et al. Early breast cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol.
2019;30:1194-1220.31161190
CardosoF
KyriakidesS
OhnoS
, et al. Early breast cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol.
2019;30:1194-1220.31161190,
CardosoF
KyriakidesS
OhnoS
, et al. Early breast cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol.
2019;30:1194-1220.31161190
-
(
KeirME
ButteMJ
FreemanGJ
SharpeAH.
PD-1 and its ligands in tolerance and immunity.
Annu Rev Immunol.
2008;26:677-704.18173375)
KeirME
ButteMJ
FreemanGJ
SharpeAH.
PD-1 and its ligands in tolerance and immunity.
Annu Rev Immunol.
2008;26:677-704.18173375
KeirME
ButteMJ
FreemanGJ
SharpeAH.
PD-1 and its ligands in tolerance and immunity.
Annu Rev Immunol.
2008;26:677-704.18173375,
KeirME
ButteMJ
FreemanGJ
SharpeAH.
PD-1 and its ligands in tolerance and immunity.
Annu Rev Immunol.
2008;26:677-704.18173375
-
S.
Topalian,
M.
Sznol,
D.
McDermott,
H.
Kluger,
R.
Carvajal,
W.
Sharfman,
J.
Brahmer,
D.
Lawrence,
M.
Atkins,
J.
Powderly,
P.
Leming,
E.
Lipson,
I.
Puzanov,
David
Smith,
J.
Taube,
J.
Wigginton,
G.
Kollia,
A.
Gupta,
D.
Pardoll,
J.
Sosman,
F.
Hodi
(2014)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 10
-
H.
Kuehn,
W.
Ouyang,
Bernice
Lo,
E.
Deenick,
J.
Niemela,
D.
Avery,
J.
Schickel,
D.
Tran,
J.
Stoddard,
Yu
Zhang,
D.
Frucht,
B.
Dumitriu,
P.
Scheinberg,
L.
Folio,
C.
Frein,
S.
Price,
C.
Koh,
T.
Heller,
C.
Seroogy,
A.
Huttenlocher,
V.
Rao,
H.
Su,
D.
Kleiner,
L.
Notarangelo,
Yajesh
Rampertaap,
K.
Olivier,
J.
McElwee,
J.
Hughes,
S.
Pittaluga,
J.
Oliveira,
E.
Meffre,
T.
Fleisher,
S.
Holland,
M.
Lenardo,
S.
Tangye,
G.
Uzel
(2014)
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
Science, 345
-
Wanqing
Chen,
R.
Zheng,
P.
Baade,
Siwei
Zhang,
H.
Zeng,
F.
Bray,
A.
Jemal,
X.
Yu,
Jie
He
(2016)
Cancer statistics in China, 2015
CA: A Cancer Journal for Clinicians, 66
-
R.
Callahan,
S.
Hurvitz
(2011)
Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease
Current Opinion in Obstetrics and Gynecology, 23
-
(
KantoffPW
HiganoCS
ShoreND
, et al. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J
Med.
2010;363:411-422.20818862)
KantoffPW
HiganoCS
ShoreND
, et al. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J
Med.
2010;363:411-422.20818862
KantoffPW
HiganoCS
ShoreND
, et al. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J
Med.
2010;363:411-422.20818862,
KantoffPW
HiganoCS
ShoreND
, et al. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J
Med.
2010;363:411-422.20818862
-
S.
Adams,
S.
Loi,
D.
Toppmeyer,
D.
Cescon,
M.
Laurentiis,
R.
Nanda,
E.
Winer,
H.
Mukai,
K.
Tamura,
A.
Armstrong,
Minetta
Liu,
H.
Iwata,
L.
Ryvo,
P.
Wimberger,
H.
Rugo,
A.
Tan,
L.
Jia,
Y.
Ding,
V.
Karantza,
P.
Schmid
(2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Annals of Oncology, 30
-
P.
Schmid,
J.
Cortés,
L.
Pusztai,
H.
McArthur,
S.
Kümmel,
J.
Bergh,
C.
Denkert,
Yeon-Hee
Park,
R.
Hui,
N.
Harbeck,
M.
Takahashi,
T.
Foukakis,
P.
Fasching,
F.
Cardoso,
M.
Untch,
L.
Jia,
V.
Karantza,
J.
Zhao,
G.
Aktan,
R.
Dent,
J.
O’Shaughnessy
(2020)
Pembrolizumab for Early Triple-Negative Breast Cancer.
The New England journal of medicine, 382 9
-
(
NersesianS
SchwartzSL
GranthamSR
, et al. NK cell infiltration is
associated with improved overall survival in solid cancers: a systematic
review and meta-analysis. Transl Oncol.
2021;14:100930.33186888)
NersesianS
SchwartzSL
GranthamSR
, et al. NK cell infiltration is
associated with improved overall survival in solid cancers: a systematic
review and meta-analysis. Transl Oncol.
2021;14:100930.33186888
NersesianS
SchwartzSL
GranthamSR
, et al. NK cell infiltration is
associated with improved overall survival in solid cancers: a systematic
review and meta-analysis. Transl Oncol.
2021;14:100930.33186888,
NersesianS
SchwartzSL
GranthamSR
, et al. NK cell infiltration is
associated with improved overall survival in solid cancers: a systematic
review and meta-analysis. Transl Oncol.
2021;14:100930.33186888
-
J.
Underwood
(1974)
Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review.
British Journal of Cancer, 30
-
(
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of
tumor-infiltrating lymphocytes in triple-negative breast cancers from two
phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG
1199. J Clin Oncol.
2014;32:2959-2966.25071121)
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of
tumor-infiltrating lymphocytes in triple-negative breast cancers from two
phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG
1199. J Clin Oncol.
2014;32:2959-2966.25071121
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of
tumor-infiltrating lymphocytes in triple-negative breast cancers from two
phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG
1199. J Clin Oncol.
2014;32:2959-2966.25071121,
AdamsS
GrayRJ
DemariaS
, et al. Prognostic value of
tumor-infiltrating lymphocytes in triple-negative breast cancers from two
phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG
1199. J Clin Oncol.
2014;32:2959-2966.25071121
-
(
PostowMA
ChesneyJ
PavlickAC
, et al. Nivolumab and ipilimumab
versus ipilimumab in untreated melanoma. N Engl J
Med.
2015;372:2006-2017.25891304)
PostowMA
ChesneyJ
PavlickAC
, et al. Nivolumab and ipilimumab
versus ipilimumab in untreated melanoma. N Engl J
Med.
2015;372:2006-2017.25891304
PostowMA
ChesneyJ
PavlickAC
, et al. Nivolumab and ipilimumab
versus ipilimumab in untreated melanoma. N Engl J
Med.
2015;372:2006-2017.25891304,
PostowMA
ChesneyJ
PavlickAC
, et al. Nivolumab and ipilimumab
versus ipilimumab in untreated melanoma. N Engl J
Med.
2015;372:2006-2017.25891304
-
Janice
Hu,
S.
Ravichandran,
Christel
Rushing,
G.
Beasley,
B.
Hanks,
Sin-Ho
Jung,
A.
Salama,
L.
Ho,
P.
Mosca
(2020)
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma
AntiCancer Research, 40
-
(
FerreiraEN
BrianeseRC
de AlmeidaRVB
, et al. Influence of BRCA1 germline
mutations in the somatic mutational burden of triple-negative breast
cancer. Transl Oncol.
2019;12:1453-1460.31419696)
FerreiraEN
BrianeseRC
de AlmeidaRVB
, et al. Influence of BRCA1 germline
mutations in the somatic mutational burden of triple-negative breast
cancer. Transl Oncol.
2019;12:1453-1460.31419696
FerreiraEN
BrianeseRC
de AlmeidaRVB
, et al. Influence of BRCA1 germline
mutations in the somatic mutational burden of triple-negative breast
cancer. Transl Oncol.
2019;12:1453-1460.31419696,
FerreiraEN
BrianeseRC
de AlmeidaRVB
, et al. Influence of BRCA1 germline
mutations in the somatic mutational burden of triple-negative breast
cancer. Transl Oncol.
2019;12:1453-1460.31419696
-
(
Ingold HeppnerB
LoiblS
DenkertC
. Tumor-infiltrating lymphocytes: a promising
biomarker in breast cancer. Breast Care
(Basel).
2016;11:96-100.27239170)
Ingold HeppnerB
LoiblS
DenkertC
. Tumor-infiltrating lymphocytes: a promising
biomarker in breast cancer. Breast Care
(Basel).
2016;11:96-100.27239170
Ingold HeppnerB
LoiblS
DenkertC
. Tumor-infiltrating lymphocytes: a promising
biomarker in breast cancer. Breast Care
(Basel).
2016;11:96-100.27239170,
Ingold HeppnerB
LoiblS
DenkertC
. Tumor-infiltrating lymphocytes: a promising
biomarker in breast cancer. Breast Care
(Basel).
2016;11:96-100.27239170
-
J.
Budczies,
M.
Bockmayr,
C.
Denkert,
F.
Klauschen,
J.
Lennerz,
Balázs
Győrffy,
M.
Dietel,
S.
Loibl,
W.
Weichert,
A.
Stenzinger
(2015)
Classical pathology and mutational load of breast cancer – integration of two worlds
The Journal of Pathology: Clinical Research, 1
-
(
RooneyMS
ShuklaSA
WuCJ
GetzG
HacohenN.
Molecular and genetic properties of tumors associated with local
immune cytolytic activity. Cell.
2015;160:48-61.25594174)
RooneyMS
ShuklaSA
WuCJ
GetzG
HacohenN.
Molecular and genetic properties of tumors associated with local
immune cytolytic activity. Cell.
2015;160:48-61.25594174
RooneyMS
ShuklaSA
WuCJ
GetzG
HacohenN.
Molecular and genetic properties of tumors associated with local
immune cytolytic activity. Cell.
2015;160:48-61.25594174,
RooneyMS
ShuklaSA
WuCJ
GetzG
HacohenN.
Molecular and genetic properties of tumors associated with local
immune cytolytic activity. Cell.
2015;160:48-61.25594174
-
H.
Wahba,
H.
El-Hadaad
(2015)
Current approaches in treatment of triple-negative breast cancer
Cancer Biology & Medicine, 12
-
C.
Anders,
L.
Carey
(2009)
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Clinical breast cancer, 9 Suppl 2
-
(
SatoH
NiimiA
YasuharaT
, et al. DNA double-strand break
repair pathway regulates PD-L1 expression in cancer cells.
Nat Commun.
2017;8:1751.)
SatoH
NiimiA
YasuharaT
, et al. DNA double-strand break
repair pathway regulates PD-L1 expression in cancer cells.
Nat Commun.
2017;8:1751.
SatoH
NiimiA
YasuharaT
, et al. DNA double-strand break
repair pathway regulates PD-L1 expression in cancer cells.
Nat Commun.
2017;8:1751.,
SatoH
NiimiA
YasuharaT
, et al. DNA double-strand break
repair pathway regulates PD-L1 expression in cancer cells.
Nat Commun.
2017;8:1751.
-
(
NolanE
SavasP
PolicheniAN
, et al. Combined immune checkpoint
blockade as a therapeutic strategy for BRCA1-mutated breast
cancer. Sci Transl Med.
2017;9:eaal4922.)
NolanE
SavasP
PolicheniAN
, et al. Combined immune checkpoint
blockade as a therapeutic strategy for BRCA1-mutated breast
cancer. Sci Transl Med.
2017;9:eaal4922.
NolanE
SavasP
PolicheniAN
, et al. Combined immune checkpoint
blockade as a therapeutic strategy for BRCA1-mutated breast
cancer. Sci Transl Med.
2017;9:eaal4922.,
NolanE
SavasP
PolicheniAN
, et al. Combined immune checkpoint
blockade as a therapeutic strategy for BRCA1-mutated breast
cancer. Sci Transl Med.
2017;9:eaal4922.
-
(
BudcziesJ
BockmayrM
DenkertC
, et al. Classical pathology and
mutational load of breast cancer—integration of two worlds.
J Pathol Clin Res.
2015;1:225-238.27499907)
BudcziesJ
BockmayrM
DenkertC
, et al. Classical pathology and
mutational load of breast cancer—integration of two worlds.
J Pathol Clin Res.
2015;1:225-238.27499907
BudcziesJ
BockmayrM
DenkertC
, et al. Classical pathology and
mutational load of breast cancer—integration of two worlds.
J Pathol Clin Res.
2015;1:225-238.27499907,
BudcziesJ
BockmayrM
DenkertC
, et al. Classical pathology and
mutational load of breast cancer—integration of two worlds.
J Pathol Clin Res.
2015;1:225-238.27499907
-
E.
Winer,
O.
Lipatov,
S.
Im,
A.
Gonçalves,
E.
Muñoz-Couselo,
K.
Lee,
P.
Schmid,
K.
Tamura,
L.
Testa,
I.
Witzel,
S.
Ohtani,
N.
Turner,
S.
Zambelli,
N.
Harbeck,
F.
André,
R.
Dent,
Xuan
Zhou,
V.
Karantza,
J.
Mejia,
J.
Cortés
(2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
The Lancet. Oncology
-
E.
Dill,
A.
Gru,
K.
Atkins,
L.
Friedman,
M.
Moore,
T.
Bullock,
J.
Cross,
P.
Dillon,
A.
Mills
(2017)
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors
The American Journal of Surgical Pathology, 41
-
Y.
Ozaki,
T.
Mukohara,
J.
Tsurutani,
M.
Takahashi,
Koji
Matsumoto,
M.
Futamura,
N.
Masuda,
S.
Kitano,
K.
Yoshimura,
H.
Minami,
T.
Takano
(2020)
Abstract PD1-03: A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial
Cancer Research, 80
-
(
RimmDL
HanG
TaubeJM
, et al. A prospective,
multi-institutional, pathologist-based assessment of 4 immunohistochemistry
assays for PD-L1 expression in non-small cell lung cancer.
JAMA Oncol.
2017;3:1051-1058.28278348)
RimmDL
HanG
TaubeJM
, et al. A prospective,
multi-institutional, pathologist-based assessment of 4 immunohistochemistry
assays for PD-L1 expression in non-small cell lung cancer.
JAMA Oncol.
2017;3:1051-1058.28278348
RimmDL
HanG
TaubeJM
, et al. A prospective,
multi-institutional, pathologist-based assessment of 4 immunohistochemistry
assays for PD-L1 expression in non-small cell lung cancer.
JAMA Oncol.
2017;3:1051-1058.28278348,
RimmDL
HanG
TaubeJM
, et al. A prospective,
multi-institutional, pathologist-based assessment of 4 immunohistochemistry
assays for PD-L1 expression in non-small cell lung cancer.
JAMA Oncol.
2017;3:1051-1058.28278348
-
N.
Mohan,
S.
Hosain,
Jun
Zhao,
Yi
Shen,
Xiao
Luo,
Jiangsong
Jiang,
Yukinori
Endo,
W.
Wu
(2019)
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells
Oncoimmunology, 8
-
Alexandra
Thomas,
Eric
Routh,
A.
Pullikuth,
G.
Jin,
Jing
Su,
J.
Chou,
K.
Hoadley,
C.
Print,
N.
Knowlton,
M.
Black,
S.
Demaria,
E.
Wang,
D.
Bedognetti,
W.
Jones,
G.
Mehta,
Michael
Gatza,
C.
Perou,
D.
Page,
P.
Triozzi,
L.
Miller
(2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Oncoimmunology, 7
-
H.
McArthur,
C.
Barker,
A.
Gucalp,
Lizza
Lebron-Zapata,
Y.
Wen,
A.
Phung,
M.
Rodine,
B.
Arnold,
Zhigang
Zhang,
A.
Ho
(2018)
A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).
Journal of Clinical Oncology, 36
-
E.
Ichihara,
D.
Harada,
Koji
Inoue,
Ken
Sato,
S.
Hosokawa,
D.
Kishino,
Kazuhiko
Watanabe,
N.
Ochi,
Naohiro
Oda,
Naofumi
Hara,
K.
Hotta,
Y.
Maeda,
K.
Kiura
(2019)
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer.
Lung cancer, 139
-
L.
Voorwerk,
M.
Slagter,
H.
Horlings,
K.
Sikorska,
K.
Vijver,
M.
Maaker,
I.
Nederlof,
R.
Kluin,
S.
Warren,
Sufey
Ong,
T.
Wiersma,
N.
Russell,
F.
Lalezari,
P.
Schouten,
N.
Bakker,
S.
Ketelaars,
D.
Peters,
C.
Lange,
E.
Werkhoven,
H.
Tinteren,
I.
Mandjes,
I.
Kemper,
Suzanne
Onderwater,
M.
Chalabi,
S.
Wilgenhof,
J.
Haanen,
R.
Salgado,
K.
Visser,
G.
Sonke,
L.
Wessels,
S.
Linn,
T.
Schumacher,
C.
Blank,
M.
Kok
(2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Nature Medicine, 25
-
S.
Adams,
P.
Schmid,
H.
Rugo,
Eric
Winer,
D.
Loirat,
A.
Awada,
D.
Cescon,
H.
Iwata,
M.
Campone,
R.
Nanda,
R.
Hui,
G.
Curigliano,
G.
Curigliano,
D.
Toppmeyer,
J.
O’Shaughnessy,
J.
O’Shaughnessy,
S.
Loi,
S.
Paluch-Shimon,
A.
Tan,
D.
Card,
J.
Zhao,
V.
Karantza,
J.
Cortés
(2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Annals of Oncology, 30
-
(
Abou AlaiwiS
XieW
NassarAH
, et al. Safety and efficacy of
restarting immune checkpoint inhibitors after clinically significant
immune-related adverse events in metastatic renal cell
carcinoma. J Immunother Cancer.
2020;8:e000144.)
Abou AlaiwiS
XieW
NassarAH
, et al. Safety and efficacy of
restarting immune checkpoint inhibitors after clinically significant
immune-related adverse events in metastatic renal cell
carcinoma. J Immunother Cancer.
2020;8:e000144.
Abou AlaiwiS
XieW
NassarAH
, et al. Safety and efficacy of
restarting immune checkpoint inhibitors after clinically significant
immune-related adverse events in metastatic renal cell
carcinoma. J Immunother Cancer.
2020;8:e000144.,
Abou AlaiwiS
XieW
NassarAH
, et al. Safety and efficacy of
restarting immune checkpoint inhibitors after clinically significant
immune-related adverse events in metastatic renal cell
carcinoma. J Immunother Cancer.
2020;8:e000144.
-
(
Sobral-LeiteM
Van de VijverK
MichautM
, et al. Assessment of PD-L1
expression across breast cancer molecular subtypes, in relation to mutation
rate, BRCA1-like status, tumor-infiltrating immune cells and
survival. Oncoimmunology.
2018;7:e1509820.)
Sobral-LeiteM
Van de VijverK
MichautM
, et al. Assessment of PD-L1
expression across breast cancer molecular subtypes, in relation to mutation
rate, BRCA1-like status, tumor-infiltrating immune cells and
survival. Oncoimmunology.
2018;7:e1509820.
Sobral-LeiteM
Van de VijverK
MichautM
, et al. Assessment of PD-L1
expression across breast cancer molecular subtypes, in relation to mutation
rate, BRCA1-like status, tumor-infiltrating immune cells and
survival. Oncoimmunology.
2018;7:e1509820.,
Sobral-LeiteM
Van de VijverK
MichautM
, et al. Assessment of PD-L1
expression across breast cancer molecular subtypes, in relation to mutation
rate, BRCA1-like status, tumor-infiltrating immune cells and
survival. Oncoimmunology.
2018;7:e1509820.
-
(
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes
and biomarker analyses of atezolizumab therapy for patients with metastatic
triple-negative breast cancer: a phase 1 study. JAMA
Oncol.
2019;5:74-82.30242306)
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes
and biomarker analyses of atezolizumab therapy for patients with metastatic
triple-negative breast cancer: a phase 1 study. JAMA
Oncol.
2019;5:74-82.30242306
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes
and biomarker analyses of atezolizumab therapy for patients with metastatic
triple-negative breast cancer: a phase 1 study. JAMA
Oncol.
2019;5:74-82.30242306,
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes
and biomarker analyses of atezolizumab therapy for patients with metastatic
triple-negative breast cancer: a phase 1 study. JAMA
Oncol.
2019;5:74-82.30242306
-
S.
Nersesian,
Sarah
Schwartz,
S.
Grantham,
Leah
MacLean,
Stacey
Lee,
Morgan
Pugh-Toole,
J.
Boudreau
(2020)
NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis
Translational Oncology, 14
-
P.
Schmid,
J.
Cortés,
R.
Dent,
L.
Pusztai,
H.
McArthur,
S.
Kümmel,
J.
Bergh,
C.
Denkert,
Yeon-Hee
Park,
R.
Hui,
N.
Harbeck,
M.
Takahashi,
M.
Untch,
P.
Fasching,
F.
Cardoso,
J.
Andersen,
D.
Patt,
M.
Danso,
Marta
Ferreira,
M.
Mouret-Reynier,
S.
Im,
J.
Ahn,
M.
Gión,
S.
Baron-Hay,
J.
Boileau,
Yu
Ding,
K.
Tryfonidis,
G.
Aktan,
V.
Karantza,
J.
O’Shaughnessy
(2022)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
The New England journal of medicine, 386 6
-
(
AndersCK
CareyLA.
Biology, metastatic patterns, and treatment of patients with
triple-negative breast cancer. Clin Breast
Cancer.
2009;9:S73-S81.)
AndersCK
CareyLA.
Biology, metastatic patterns, and treatment of patients with
triple-negative breast cancer. Clin Breast
Cancer.
2009;9:S73-S81.
AndersCK
CareyLA.
Biology, metastatic patterns, and treatment of patients with
triple-negative breast cancer. Clin Breast
Cancer.
2009;9:S73-S81.,
AndersCK
CareyLA.
Biology, metastatic patterns, and treatment of patients with
triple-negative breast cancer. Clin Breast
Cancer.
2009;9:S73-S81.
-
(
StojanovicA
FieglerN
Brunner-WeinzierlM
CerwenkaA.
CTLA-4 is expressed by activated mouse NK cells and inhibits NK
Cell IFN-gamma production in response to mature dendritic
cells. J Immunol.
2014;192:4184-4191.24688023)
StojanovicA
FieglerN
Brunner-WeinzierlM
CerwenkaA.
CTLA-4 is expressed by activated mouse NK cells and inhibits NK
Cell IFN-gamma production in response to mature dendritic
cells. J Immunol.
2014;192:4184-4191.24688023
StojanovicA
FieglerN
Brunner-WeinzierlM
CerwenkaA.
CTLA-4 is expressed by activated mouse NK cells and inhibits NK
Cell IFN-gamma production in response to mature dendritic
cells. J Immunol.
2014;192:4184-4191.24688023,
StojanovicA
FieglerN
Brunner-WeinzierlM
CerwenkaA.
CTLA-4 is expressed by activated mouse NK cells and inhibits NK
Cell IFN-gamma production in response to mature dendritic
cells. J Immunol.
2014;192:4184-4191.24688023
-
T.
Fleisher
(2015)
Immune Dysregulation in Human Subjects With Heterozygous Germline Mutations in CTLA4
Pediatrics, 136
-
(
LoiS
MichielsS
SalgadoR
, et al. Tumor infiltrating
lymphocytes are prognostic in triple negative breast cancer and predictive
for trastuzumab benefit in early breast cancer: results from the FinHER
trial. Ann Oncol.
2014;25:1544-1550.24608200)
LoiS
MichielsS
SalgadoR
, et al. Tumor infiltrating
lymphocytes are prognostic in triple negative breast cancer and predictive
for trastuzumab benefit in early breast cancer: results from the FinHER
trial. Ann Oncol.
2014;25:1544-1550.24608200
LoiS
MichielsS
SalgadoR
, et al. Tumor infiltrating
lymphocytes are prognostic in triple negative breast cancer and predictive
for trastuzumab benefit in early breast cancer: results from the FinHER
trial. Ann Oncol.
2014;25:1544-1550.24608200,
LoiS
MichielsS
SalgadoR
, et al. Tumor infiltrating
lymphocytes are prognostic in triple negative breast cancer and predictive
for trastuzumab benefit in early breast cancer: results from the FinHER
trial. Ann Oncol.
2014;25:1544-1550.24608200
-
(
VoorwerkL
SlagterM
HorlingsHM
, et al. Immune induction strategies
in metastatic triple-negative breast cancer to enhance the sensitivity to
PD-1 blockade: the TONIC trial. Nat Med.
2019;25:920-928.31086347)
VoorwerkL
SlagterM
HorlingsHM
, et al. Immune induction strategies
in metastatic triple-negative breast cancer to enhance the sensitivity to
PD-1 blockade: the TONIC trial. Nat Med.
2019;25:920-928.31086347
VoorwerkL
SlagterM
HorlingsHM
, et al. Immune induction strategies
in metastatic triple-negative breast cancer to enhance the sensitivity to
PD-1 blockade: the TONIC trial. Nat Med.
2019;25:920-928.31086347,
VoorwerkL
SlagterM
HorlingsHM
, et al. Immune induction strategies
in metastatic triple-negative breast cancer to enhance the sensitivity to
PD-1 blockade: the TONIC trial. Nat Med.
2019;25:920-928.31086347
-
D.
Rimm,
Gang
Han,
J.
Taube,
E.
Yi,
J.
Bridge,
D.
Flieder,
R.
Homer,
W.
West,
Hong
Wu,
A.
Roden,
J.
Fujimoto,
Hui
Yu,
R.
Anders,
Ashley
Kowalewski,
C.
Rivard,
Jamaal
Rehman,
C.
Batenchuk,
Virginia
Burns,
F.
Hirsch,
I.
Wistuba
(2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
JAMA Oncology, 3
-
(
SchmidP
DentR
O’ShaughnessyJ
. Pembrolizumab for early triple-negative breast
cancer. Reply. N Engl J Med.
2020;382:e108.)
SchmidP
DentR
O’ShaughnessyJ
. Pembrolizumab for early triple-negative breast
cancer. Reply. N Engl J Med.
2020;382:e108.
SchmidP
DentR
O’ShaughnessyJ
. Pembrolizumab for early triple-negative breast
cancer. Reply. N Engl J Med.
2020;382:e108.,
SchmidP
DentR
O’ShaughnessyJ
. Pembrolizumab for early triple-negative breast
cancer. Reply. N Engl J Med.
2020;382:e108.
-
Estefania
Julia,
A.
Amante,
M.
Pampena,
J.
Mordoh,
E.
Levy
(2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Frontiers in Immunology, 9
-
(
PopatS
HubnerR
HoulstonRS.
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol.
2005;23:609-618.15659508)
PopatS
HubnerR
HoulstonRS.
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol.
2005;23:609-618.15659508
PopatS
HubnerR
HoulstonRS.
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol.
2005;23:609-618.15659508,
PopatS
HubnerR
HoulstonRS.
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol.
2005;23:609-618.15659508
-
(
Santa-MariaCA
KatoT
ParkJH
, et al. A pilot study of durvalumab
and tremelimumab and immunogenomic dynamics in metastatic breast
cancer. Oncotarget.
2018;9:18985-18996.29721177)
Santa-MariaCA
KatoT
ParkJH
, et al. A pilot study of durvalumab
and tremelimumab and immunogenomic dynamics in metastatic breast
cancer. Oncotarget.
2018;9:18985-18996.29721177
Santa-MariaCA
KatoT
ParkJH
, et al. A pilot study of durvalumab
and tremelimumab and immunogenomic dynamics in metastatic breast
cancer. Oncotarget.
2018;9:18985-18996.29721177,
Santa-MariaCA
KatoT
ParkJH
, et al. A pilot study of durvalumab
and tremelimumab and immunogenomic dynamics in metastatic breast
cancer. Oncotarget.
2018;9:18985-18996.29721177
-
E.
Senkus,
F.
Cardoso,
O.
Pagani
(2014)
Time for more optimism in metastatic breast cancer?
Cancer treatment reviews, 40 2
-
C.
Criscitiello,
M.
Bayar,
G.
Curigliano,
F.
Symmans,
C.
Desmedt,
H.
Bonnefoi,
B.
Sinn,
G.
Pruneri,
C.
Vicier,
J.
Pierga,
C.
Denkert,
S.
Loibl,
C.
Sotiriou,
S.
Michiels,
F.
André
(2018)
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer
Annals of Oncology, 29
-
(
La RoccaE
DispinzieriM
LozzaL
, et al. Radiotherapy with the
anti-programmed cell death ligand-1 immune checkpoint blocker avelumab:
acute toxicities in triple-negative breast cancer.
Med Oncol.
2018;36:4.30443687)
La RoccaE
DispinzieriM
LozzaL
, et al. Radiotherapy with the
anti-programmed cell death ligand-1 immune checkpoint blocker avelumab:
acute toxicities in triple-negative breast cancer.
Med Oncol.
2018;36:4.30443687
La RoccaE
DispinzieriM
LozzaL
, et al. Radiotherapy with the
anti-programmed cell death ligand-1 immune checkpoint blocker avelumab:
acute toxicities in triple-negative breast cancer.
Med Oncol.
2018;36:4.30443687,
La RoccaE
DispinzieriM
LozzaL
, et al. Radiotherapy with the
anti-programmed cell death ligand-1 immune checkpoint blocker avelumab:
acute toxicities in triple-negative breast cancer.
Med Oncol.
2018;36:4.30443687
-
(
WahbaHA
El-HadaadHA.
Current approaches in treatment of triple-negative breast
cancer. Cancer Biol Med.
2015;12:106-116.26175926)
WahbaHA
El-HadaadHA.
Current approaches in treatment of triple-negative breast
cancer. Cancer Biol Med.
2015;12:106-116.26175926
WahbaHA
El-HadaadHA.
Current approaches in treatment of triple-negative breast
cancer. Cancer Biol Med.
2015;12:106-116.26175926,
WahbaHA
El-HadaadHA.
Current approaches in treatment of triple-negative breast
cancer. Cancer Biol Med.
2015;12:106-116.26175926
-
F.
Ghiringhelli,
C.
Ménard,
P.
Puig,
S.
Ladoire,
S.
Roux,
F.
Martin,
E.
Solary,
A.
Cesne,
L.
Zitvogel,
B.
Chauffert
(2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Cancer Immunology, Immunotherapy, 56
-
F.
Cardoso,
S.
Kyriakides,
S.
Ohno,
F.
Penault-Llorca,
P.
Poortmans,
I.
Rubio,
S.
Zackrisson,
E.
Senkus
(2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology
-
L.
Emens,
C.
Cruz,
J.
Eder,
F.
Braiteh,
C.
Chung,
S.
Tolaney,
I.
Kuter,
R.
Nanda,
P.
Cassier,
J.
Delord,
M.
Gordon,
E.
Elgabry,
Ching-Wei
Chang,
Indrani
Sarkar,
W.
Grossman,
C.
O'Hear,
M.
Fassò,
L.
Molinero,
P.
Schmid
(2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study
JAMA Oncology, 5
-
(
CareyLA
DeesEC
SawyerL
, et al. The triple negative paradox:
primary tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res.
2007;13:2329-2334.17438091)
CareyLA
DeesEC
SawyerL
, et al. The triple negative paradox:
primary tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res.
2007;13:2329-2334.17438091
CareyLA
DeesEC
SawyerL
, et al. The triple negative paradox:
primary tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res.
2007;13:2329-2334.17438091,
CareyLA
DeesEC
SawyerL
, et al. The triple negative paradox:
primary tumor chemosensitivity of breast cancer subtypes.
Clin Cancer Res.
2007;13:2329-2334.17438091
-
(
BoyerinasB
JochemsC
FantiniM
, et al. Antibody-dependent cellular
cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C)
on human tumor cells. Cancer Immunol Res.
2015;3:1148-1157.26014098)
BoyerinasB
JochemsC
FantiniM
, et al. Antibody-dependent cellular
cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C)
on human tumor cells. Cancer Immunol Res.
2015;3:1148-1157.26014098
BoyerinasB
JochemsC
FantiniM
, et al. Antibody-dependent cellular
cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C)
on human tumor cells. Cancer Immunol Res.
2015;3:1148-1157.26014098,
BoyerinasB
JochemsC
FantiniM
, et al. Antibody-dependent cellular
cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C)
on human tumor cells. Cancer Immunol Res.
2015;3:1148-1157.26014098
-
S.
Loibl,
A.
Schneeweiss,
J.
Huober,
M.
Braun,
J.
Rey,
J.
Blohmer,
J.
Furlanetto,
D.
Zahm,
C.
Hanusch,
J.
Thomalla,
C.
Jackisch,
P.
Staib,
T.
Link,
K.
Rhiem,
C.
Solbach,
P.
Fasching,
N.
Burchardi,
C.
Denkert,
M.
Untch
(2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Journal of Clinical Oncology
-
(
BauerKR
BrownM
CressRD
PariseCA
CaggianoV.
Descriptive analysis of estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and HER2-negative invasive breast
cancer, the so-called triple-negative phenotype: a population-based study
from the California cancer Registry.
Cancer.
2007;109:1721-1728.17387718)
BauerKR
BrownM
CressRD
PariseCA
CaggianoV.
Descriptive analysis of estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and HER2-negative invasive breast
cancer, the so-called triple-negative phenotype: a population-based study
from the California cancer Registry.
Cancer.
2007;109:1721-1728.17387718
BauerKR
BrownM
CressRD
PariseCA
CaggianoV.
Descriptive analysis of estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and HER2-negative invasive breast
cancer, the so-called triple-negative phenotype: a population-based study
from the California cancer Registry.
Cancer.
2007;109:1721-1728.17387718,
BauerKR
BrownM
CressRD
PariseCA
CaggianoV.
Descriptive analysis of estrogen receptor (ER)-negative,
progesterone receptor (PR)-negative, and HER2-negative invasive breast
cancer, the so-called triple-negative phenotype: a population-based study
from the California cancer Registry.
Cancer.
2007;109:1721-1728.17387718
-
(
Matthew HellmannHJW
. Management of advanced non-small cell lung
cancer lacking a driver mutation: immunotherapy. https://www.uptodate.com/contents/management-of-advanced-non-small-cell-lung-cancer-lacking-a-driver-mutation-immunotherapy.
Published 2020. Updated March
17, 2020.)
Matthew HellmannHJW
. Management of advanced non-small cell lung
cancer lacking a driver mutation: immunotherapy. https://www.uptodate.com/contents/management-of-advanced-non-small-cell-lung-cancer-lacking-a-driver-mutation-immunotherapy.
Published 2020. Updated March
17, 2020.
Matthew HellmannHJW
. Management of advanced non-small cell lung
cancer lacking a driver mutation: immunotherapy. https://www.uptodate.com/contents/management-of-advanced-non-small-cell-lung-cancer-lacking-a-driver-mutation-immunotherapy.
Published 2020. Updated March
17, 2020.,
Matthew HellmannHJW
. Management of advanced non-small cell lung
cancer lacking a driver mutation: immunotherapy. https://www.uptodate.com/contents/management-of-advanced-non-small-cell-lung-cancer-lacking-a-driver-mutation-immunotherapy.
Published 2020. Updated March
17, 2020.
-
L.
Zavalishina,
I.
Tsimafeyeu,
P.
Povilaitite,
G.
Raskin,
Y.
Andreeva,
A.
Petrov,
E.
Kharitonova,
A.
Rumyantsev,
I.
Pugach,
G.
Frank,
S.
Tjulandin
(2018)
RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer
Virchows Archiv, 473
-
(
ChenW
ZhengR
BaadePD
, et al. Cancer statistics in China,
2015. CA Cancer J Clin.
2016;66:115-132.26808342)
ChenW
ZhengR
BaadePD
, et al. Cancer statistics in China,
2015. CA Cancer J Clin.
2016;66:115-132.26808342
ChenW
ZhengR
BaadePD
, et al. Cancer statistics in China,
2015. CA Cancer J Clin.
2016;66:115-132.26808342,
ChenW
ZhengR
BaadePD
, et al. Cancer statistics in China,
2015. CA Cancer J Clin.
2016;66:115-132.26808342
-
L.
Pfannenstiel,
S.
Lam,
L.
Emens,
E.
Jaffee,
T.
Armstrong
(2010)
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.
Cellular immunology, 263 1
-
(2007)
, the so - called triple - negative phenotype : a population - based study from the California cancer Registry
-
(
GuermonprezP
ValladeauJ
ZitvogelL
TheryC
AmigorenaS.
Antigen presentation and T cell stimulation by dendritic
cells. Annu Rev Immunol.
2002;20:621-667.11861614)
GuermonprezP
ValladeauJ
ZitvogelL
TheryC
AmigorenaS.
Antigen presentation and T cell stimulation by dendritic
cells. Annu Rev Immunol.
2002;20:621-667.11861614
GuermonprezP
ValladeauJ
ZitvogelL
TheryC
AmigorenaS.
Antigen presentation and T cell stimulation by dendritic
cells. Annu Rev Immunol.
2002;20:621-667.11861614,
GuermonprezP
ValladeauJ
ZitvogelL
TheryC
AmigorenaS.
Antigen presentation and T cell stimulation by dendritic
cells. Annu Rev Immunol.
2002;20:621-667.11861614
-
(
AlvarezIB
PasquinelliV
JuradoJO
, et al. Role played by the
programmed death-1-programmed death ligand pathway during innate immunity
against Mycobacterium tuberculosis. J Infect
Dis.
2010;202:524-532.20617899)
AlvarezIB
PasquinelliV
JuradoJO
, et al. Role played by the
programmed death-1-programmed death ligand pathway during innate immunity
against Mycobacterium tuberculosis. J Infect
Dis.
2010;202:524-532.20617899
AlvarezIB
PasquinelliV
JuradoJO
, et al. Role played by the
programmed death-1-programmed death ligand pathway during innate immunity
against Mycobacterium tuberculosis. J Infect
Dis.
2010;202:524-532.20617899,
AlvarezIB
PasquinelliV
JuradoJO
, et al. Role played by the
programmed death-1-programmed death ligand pathway during innate immunity
against Mycobacterium tuberculosis. J Infect
Dis.
2010;202:524-532.20617899
-
(
CriscitielloC
BayarMA
CuriglianoG
, et al. A gene signature to predict
high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and
outcome in patients with triple-negative breast cancer.
Ann Oncol.
2018;29:162-169.29077781)
CriscitielloC
BayarMA
CuriglianoG
, et al. A gene signature to predict
high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and
outcome in patients with triple-negative breast cancer.
Ann Oncol.
2018;29:162-169.29077781
CriscitielloC
BayarMA
CuriglianoG
, et al. A gene signature to predict
high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and
outcome in patients with triple-negative breast cancer.
Ann Oncol.
2018;29:162-169.29077781,
CriscitielloC
BayarMA
CuriglianoG
, et al. A gene signature to predict
high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and
outcome in patients with triple-negative breast cancer.
Ann Oncol.
2018;29:162-169.29077781
-
(2020)
EMA reminds physicians to use Tecentriq with nab - paclitaxel for treating breast cancer
-
I.
Alvarez,
V.
Pasquinelli,
J.
Jurado,
E.
Abbate,
R.
Musella,
S.
Barrera,
V.
García
(2010)
Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis.
The Journal of infectious diseases, 202 4
-
J.
Wolchok,
B.
Neyns,
G.
Linette,
S.
Négrier,
J.
Lutzky,
L.
Thomas,
W.
Waterfield,
D.
Schadendorf,
M.
Smylie,
T.
Guthrie,
J.
Grob,
J.
Chesney,
K.
Chin,
Kun
Chen,
A.
Hoos,
S.
O'Day,
C.
Lebbé
(2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
The Lancet. Oncology, 11 2
-
C.
Criscitiello,
A.
Esposito,
D.
Trapani,
G.
Curigliano
(2016)
Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.
Cancer treatment reviews, 50
-
(
PfannenstielLW
LamSS
EmensLA
JaffeeEM
ArmstrongTD.
Paclitaxel enhances early dendritic cell maturation and function
through TLR4 signaling in mice. Cell
Immunol.
2010;263:79-87.20346445)
PfannenstielLW
LamSS
EmensLA
JaffeeEM
ArmstrongTD.
Paclitaxel enhances early dendritic cell maturation and function
through TLR4 signaling in mice. Cell
Immunol.
2010;263:79-87.20346445
PfannenstielLW
LamSS
EmensLA
JaffeeEM
ArmstrongTD.
Paclitaxel enhances early dendritic cell maturation and function
through TLR4 signaling in mice. Cell
Immunol.
2010;263:79-87.20346445,
PfannenstielLW
LamSS
EmensLA
JaffeeEM
ArmstrongTD.
Paclitaxel enhances early dendritic cell maturation and function
through TLR4 signaling in mice. Cell
Immunol.
2010;263:79-87.20346445
-
L.
Carey,
E.
Dees,
L.
Sawyer,
Lisa
Gatti,
D.
Moore,
F.
Collichio,
D.
Ollila,
Carolyn
Sartor,
M.
Graham,
C.
Perou
(2007)
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Clinical Cancer Research, 13
-
Y.
Wen,
E.
Brogi,
Z.
Zeng,
Muzaffar
Akram,
Jeffrey
Catalano,
P.
Paty,
L.
Norton,
J.
Shia
(2012)
DNA Mismatch Repair Deficiency in Breast Carcinoma: A Pilot Study of Triple-negative and Non–Triple-negative Tumors
The American Journal of Surgical Pathology, 36
-
(
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology.
Mutational landscape determines sensitivity to PD-1 blockade in non-small
cell lung cancer. Science.
2015;348:124-128.25765070)
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology.
Mutational landscape determines sensitivity to PD-1 blockade in non-small
cell lung cancer. Science.
2015;348:124-128.25765070
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology.
Mutational landscape determines sensitivity to PD-1 blockade in non-small
cell lung cancer. Science.
2015;348:124-128.25765070,
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology.
Mutational landscape determines sensitivity to PD-1 blockade in non-small
cell lung cancer. Science.
2015;348:124-128.25765070
-
P.
Schmid,
R.
Salgado,
Yeon-Hee
Park,
E.
Muñoz-Couselo,
Sung-Bae
Kim,
J.
Sohn,
S.
Im,
T.
Foukakis,
S.
Kuemmel,
R.
Dent,
L.
Yin,
A.
Wang,
K.
Tryfonidis,
V.
Karantza,
J.
Cortés,
S.
Loi
(2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Annals of oncology : official journal of the European Society for Medical Oncology
-
(
WinerEP
LipatovO
ImSA
, et al. Pembrolizumab versus
investigator-choice chemotherapy for metastatic triple-negative breast
cancer (KEYNOTE-119): a randomised, open-label, phase 3
trial. Lancet Oncol.
2021;22:499-511.33676601)
WinerEP
LipatovO
ImSA
, et al. Pembrolizumab versus
investigator-choice chemotherapy for metastatic triple-negative breast
cancer (KEYNOTE-119): a randomised, open-label, phase 3
trial. Lancet Oncol.
2021;22:499-511.33676601
WinerEP
LipatovO
ImSA
, et al. Pembrolizumab versus
investigator-choice chemotherapy for metastatic triple-negative breast
cancer (KEYNOTE-119): a randomised, open-label, phase 3
trial. Lancet Oncol.
2021;22:499-511.33676601,
WinerEP
LipatovO
ImSA
, et al. Pembrolizumab versus
investigator-choice chemotherapy for metastatic triple-negative breast
cancer (KEYNOTE-119): a randomised, open-label, phase 3
trial. Lancet Oncol.
2021;22:499-511.33676601
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2019)
Cancer statistics, 2019
CA: A Cancer Journal for Clinicians, 69
-
A.
Stojanovic,
Nathalie
Fiegler,
M.
Brunner‐Weinzierl,
A.
Cerwenka
(2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
The Journal of Immunology, 192
-
(
SalgadoR
DenkertC
DemariaS
, et al. The evaluation of
tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by
an International TILs Working Group 2014. Ann
Oncol.
2015;26:259-271.25214542)
SalgadoR
DenkertC
DemariaS
, et al. The evaluation of
tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by
an International TILs Working Group 2014. Ann
Oncol.
2015;26:259-271.25214542
SalgadoR
DenkertC
DemariaS
, et al. The evaluation of
tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by
an International TILs Working Group 2014. Ann
Oncol.
2015;26:259-271.25214542,
SalgadoR
DenkertC
DemariaS
, et al. The evaluation of
tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by
an International TILs Working Group 2014. Ann
Oncol.
2015;26:259-271.25214542
-
(
AnsellSM
LesokhinAM
BorrelloI
, et al. PD-1 blockade with nivolumab
in relapsed or refractory Hodgkin’s lymphoma. N Engl
J Med.
2015;372:311-319.25482239)
AnsellSM
LesokhinAM
BorrelloI
, et al. PD-1 blockade with nivolumab
in relapsed or refractory Hodgkin’s lymphoma. N Engl
J Med.
2015;372:311-319.25482239
AnsellSM
LesokhinAM
BorrelloI
, et al. PD-1 blockade with nivolumab
in relapsed or refractory Hodgkin’s lymphoma. N Engl
J Med.
2015;372:311-319.25482239,
AnsellSM
LesokhinAM
BorrelloI
, et al. PD-1 blockade with nivolumab
in relapsed or refractory Hodgkin’s lymphoma. N Engl
J Med.
2015;372:311-319.25482239
-
(
XiaoY
MaD
ZhaoS
, et al. Multi-omics profiling
reveals distinct microenvironment characterization and suggests immune
escape mechanisms of triple-negative breast cancer.
Clin Cancer Res.
2019;25:5002-5014.30837276)
XiaoY
MaD
ZhaoS
, et al. Multi-omics profiling
reveals distinct microenvironment characterization and suggests immune
escape mechanisms of triple-negative breast cancer.
Clin Cancer Res.
2019;25:5002-5014.30837276
XiaoY
MaD
ZhaoS
, et al. Multi-omics profiling
reveals distinct microenvironment characterization and suggests immune
escape mechanisms of triple-negative breast cancer.
Clin Cancer Res.
2019;25:5002-5014.30837276,
XiaoY
MaD
ZhaoS
, et al. Multi-omics profiling
reveals distinct microenvironment characterization and suggests immune
escape mechanisms of triple-negative breast cancer.
Clin Cancer Res.
2019;25:5002-5014.30837276
-
(
MichotJM
BigenwaldC
ChampiatS
, et al. Immune-related adverse
events with immune checkpoint blockade: a comprehensive
review. Eur J Cancer.
2016;54:139-148.26765102)
MichotJM
BigenwaldC
ChampiatS
, et al. Immune-related adverse
events with immune checkpoint blockade: a comprehensive
review. Eur J Cancer.
2016;54:139-148.26765102
MichotJM
BigenwaldC
ChampiatS
, et al. Immune-related adverse
events with immune checkpoint blockade: a comprehensive
review. Eur J Cancer.
2016;54:139-148.26765102,
MichotJM
BigenwaldC
ChampiatS
, et al. Immune-related adverse
events with immune checkpoint blockade: a comprehensive
review. Eur J Cancer.
2016;54:139-148.26765102
-
S.
Loi,
S.
Adams,
P.
Schmid,
J.
Cortés,
D.
Cescon,
E.
Winer,
D.
Toppmeyer,
H.
Rugo,
M.
Laurentiis,
R.
Nanda,
H.
Iwata,
A.
Awada,
A.
Tan,
A.
Wang,
G.
Aktan,
V.
Karantza,
R.
Salgado
(2017)
LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086
Annals of Oncology, 28
-
A.
Safonov,
T.
Jiang,
G.
Bianchini,
Balázs
Győrffy,
T.
Karn,
C.
Hatzis,
L.
Pusztai
(2017)
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer.
Cancer research, 77 12
-
R.
Kleef,
R.
Moss,
A.
Szász,
A.
Bohdjalian,
H.
Bojar,
T.
Bakács
(2018)
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2
Integrative Cancer Therapies, 17
-
S.
Ansell,
A.
Lesokhin,
I.
Borrello,
A.
Halwani,
E.
Scott,
M.
Gutierrez,
S.
Schuster,
M.
Millenson,
D.
Cattry,
G.
Freeman,
S.
Rodig,
B.
Chapuy,
A.
Ligon,
Lili
Zhu,
J.
Grosso,
S.
Kim,
J.
Timmerman,
M.
Shipp,
P.
Armand
(2015)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
The New England journal of medicine, 372 4
-
(
DingX
ChenQ
YangZ
, et al. Clinicopathological and
prognostic value of PD-L1 in urothelial carcinoma: a
meta-analysis. Cancer Manag Res.
2019;11:4171-4184.31190987)
DingX
ChenQ
YangZ
, et al. Clinicopathological and
prognostic value of PD-L1 in urothelial carcinoma: a
meta-analysis. Cancer Manag Res.
2019;11:4171-4184.31190987
DingX
ChenQ
YangZ
, et al. Clinicopathological and
prognostic value of PD-L1 in urothelial carcinoma: a
meta-analysis. Cancer Manag Res.
2019;11:4171-4184.31190987,
DingX
ChenQ
YangZ
, et al. Clinicopathological and
prognostic value of PD-L1 in urothelial carcinoma: a
meta-analysis. Cancer Manag Res.
2019;11:4171-4184.31190987
-
Benjamin
Boyerinas,
C.
Jochems,
M.
Fantini,
C.
Heery,
J.
Gulley,
K.
Tsang,
J.
Schlom
(2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Cancer Immunology Research, 3
-
(2016)
Abstract P 4 - 0401 : PDL - 1 expression in primary breast cancers with germline mutations in BRCA 1 and 2
-
(
KleefR
MossR
SzaszAM
BohdjalianA
BojarH
BakacsT.
Complete clinical remission of stage IV triple-negative breast
cancer lung metastasis administering low-dose immune checkpoint blockade in
combination with hyperthermia and interleukin-2.
Integr Cancer Ther.
2018;17:1297-1303.30193538)
KleefR
MossR
SzaszAM
BohdjalianA
BojarH
BakacsT.
Complete clinical remission of stage IV triple-negative breast
cancer lung metastasis administering low-dose immune checkpoint blockade in
combination with hyperthermia and interleukin-2.
Integr Cancer Ther.
2018;17:1297-1303.30193538
KleefR
MossR
SzaszAM
BohdjalianA
BojarH
BakacsT.
Complete clinical remission of stage IV triple-negative breast
cancer lung metastasis administering low-dose immune checkpoint blockade in
combination with hyperthermia and interleukin-2.
Integr Cancer Ther.
2018;17:1297-1303.30193538,
KleefR
MossR
SzaszAM
BohdjalianA
BojarH
BakacsT.
Complete clinical remission of stage IV triple-negative breast
cancer lung metastasis administering low-dose immune checkpoint blockade in
combination with hyperthermia and interleukin-2.
Integr Cancer Ther.
2018;17:1297-1303.30193538
-
(
McArthurH
BarkerC
GucalpA
, et al. A single-arm, phase II study
assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in
metastatic triple negative breast cancer (mTNBC). J
Clin Oncol.
2018;36:14.29035645)
McArthurH
BarkerC
GucalpA
, et al. A single-arm, phase II study
assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in
metastatic triple negative breast cancer (mTNBC). J
Clin Oncol.
2018;36:14.29035645
McArthurH
BarkerC
GucalpA
, et al. A single-arm, phase II study
assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in
metastatic triple negative breast cancer (mTNBC). J
Clin Oncol.
2018;36:14.29035645,
McArthurH
BarkerC
GucalpA
, et al. A single-arm, phase II study
assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in
metastatic triple negative breast cancer (mTNBC). J
Clin Oncol.
2018;36:14.29035645
-
(
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in
triple-negative breast cancer. Cancer Immunol
Res.
2014;2:361-370.24764583)
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in
triple-negative breast cancer. Cancer Immunol
Res.
2014;2:361-370.24764583
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in
triple-negative breast cancer. Cancer Immunol
Res.
2014;2:361-370.24764583,
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in
triple-negative breast cancer. Cancer Immunol
Res.
2014;2:361-370.24764583
-
S.
Vinayak,
S.
Tolaney,
L.
Schwartzberg,
M.
Mita,
G.
McCann,
A.
Tan,
Andrea
Wahner-Hendrickson,
A.
Forero,
C.
Anders,
G.
Wulf,
P.
Dillon,
F.
Lynce,
C.
Zarwan,
J.
Erban,
Yinghui
Zhou,
N.
Buerstatte,
J.
Graham,
Sujata
Arora,
B.
Dezube,
M.
Telli
(2019)
Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
JAMA oncology
-
(
BonottoM
GerratanaL
PolettoE
, et al. Measures of outcome in
metastatic breast cancer: insights from a real-world
scenario. Oncologist.
2014;19:608-615.24794159)
BonottoM
GerratanaL
PolettoE
, et al. Measures of outcome in
metastatic breast cancer: insights from a real-world
scenario. Oncologist.
2014;19:608-615.24794159
BonottoM
GerratanaL
PolettoE
, et al. Measures of outcome in
metastatic breast cancer: insights from a real-world
scenario. Oncologist.
2014;19:608-615.24794159,
BonottoM
GerratanaL
PolettoE
, et al. Measures of outcome in
metastatic breast cancer: insights from a real-world
scenario. Oncologist.
2014;19:608-615.24794159
-
(
MohanN
HosainS
ZhaoJ
, et al. Atezolizumab potentiates
Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell
invasion and motility in PD-L1(+) triple negative breast cancer
cells. Oncoimmunology.
2019;8:e1624128.)
MohanN
HosainS
ZhaoJ
, et al. Atezolizumab potentiates
Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell
invasion and motility in PD-L1(+) triple negative breast cancer
cells. Oncoimmunology.
2019;8:e1624128.
MohanN
HosainS
ZhaoJ
, et al. Atezolizumab potentiates
Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell
invasion and motility in PD-L1(+) triple negative breast cancer
cells. Oncoimmunology.
2019;8:e1624128.,
MohanN
HosainS
ZhaoJ
, et al. Atezolizumab potentiates
Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell
invasion and motility in PD-L1(+) triple negative breast cancer
cells. Oncoimmunology.
2019;8:e1624128.
-
D.
Jiang,
A.
Fyles,
L.
Nguyen,
B.
Neel,
A.
Sacher,
R.
Rottapel,
Ben
Wang,
P.
Ohashi,
S.
Sridhar
(2019)
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
Oncotarget, 10
-
(
WolchokJD
NeynsB
LinetteG
, et al. Ipilimumab monotherapy in
patients with pretreated advanced melanoma: a randomised, double-blind,
multicentre, phase 2, dose-ranging study. Lancet
Oncol.
2010;11:155-164.20004617)
WolchokJD
NeynsB
LinetteG
, et al. Ipilimumab monotherapy in
patients with pretreated advanced melanoma: a randomised, double-blind,
multicentre, phase 2, dose-ranging study. Lancet
Oncol.
2010;11:155-164.20004617
WolchokJD
NeynsB
LinetteG
, et al. Ipilimumab monotherapy in
patients with pretreated advanced melanoma: a randomised, double-blind,
multicentre, phase 2, dose-ranging study. Lancet
Oncol.
2010;11:155-164.20004617,
WolchokJD
NeynsB
LinetteG
, et al. Ipilimumab monotherapy in
patients with pretreated advanced melanoma: a randomised, double-blind,
multicentre, phase 2, dose-ranging study. Lancet
Oncol.
2010;11:155-164.20004617
-
E.
Buchbinder,
Anupam
Desai
(2016)
CTLA-4 and PD-1 Pathways
American Journal of Clinical Oncology, 39
-
(
LoiSA
damsS
SchmidP
, et al. Relationship between tumor
infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro)
in metastatic triple-negative breast cancer (mTNBC): results from
KEYNOTE-086. Ann Oncol.
2017;28:V608.)
LoiSA
damsS
SchmidP
, et al. Relationship between tumor
infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro)
in metastatic triple-negative breast cancer (mTNBC): results from
KEYNOTE-086. Ann Oncol.
2017;28:V608.
LoiSA
damsS
SchmidP
, et al. Relationship between tumor
infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro)
in metastatic triple-negative breast cancer (mTNBC): results from
KEYNOTE-086. Ann Oncol.
2017;28:V608.,
LoiSA
damsS
SchmidP
, et al. Relationship between tumor
infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro)
in metastatic triple-negative breast cancer (mTNBC): results from
KEYNOTE-086. Ann Oncol.
2017;28:V608.
-
(
BrownLC
LoiS.
Immune checkpoint inhibition in the treatment of early stage
triple negative breast cancer: 2021 update.
Breast.
2022;62:S29-S33.)
BrownLC
LoiS.
Immune checkpoint inhibition in the treatment of early stage
triple negative breast cancer: 2021 update.
Breast.
2022;62:S29-S33.
BrownLC
LoiS.
Immune checkpoint inhibition in the treatment of early stage
triple negative breast cancer: 2021 update.
Breast.
2022;62:S29-S33.,
BrownLC
LoiS.
Immune checkpoint inhibition in the treatment of early stage
triple negative breast cancer: 2021 update.
Breast.
2022;62:S29-S33.
-
U
S
-
J.
Weber,
K.
Kähler,
A.
Hauschild
(2012)
Management of immune-related adverse events and kinetics of response with ipilimumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
-
(
BuchbinderEI
DesaiA.
CTLA-4 and PD-1 pathways: similarities, differences, and
implications of their inhibition. Am J Clin
Oncol.
2016;39:98-106.26558876)
BuchbinderEI
DesaiA.
CTLA-4 and PD-1 pathways: similarities, differences, and
implications of their inhibition. Am J Clin
Oncol.
2016;39:98-106.26558876
BuchbinderEI
DesaiA.
CTLA-4 and PD-1 pathways: similarities, differences, and
implications of their inhibition. Am J Clin
Oncol.
2016;39:98-106.26558876,
BuchbinderEI
DesaiA.
CTLA-4 and PD-1 pathways: similarities, differences, and
implications of their inhibition. Am J Clin
Oncol.
2016;39:98-106.26558876